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1.0 ABSTRACT 
Bioavailability of nevirapine from the currently available tablet dosage form remains 
a concern for effective control of  HIV infection. The present study attempted to develop 
nevirapine nanoparticles using human serum albumin (HSA) as polymer in varied 
concentrations and to evaluate for physico-chemical, in-vitro and in-vivo release  
characteristics. Three formulations F1, F2, and F3 were developed using drug:polymer ratios 
1:1,1:2,and1:4 respectively by desolvation method. The particle size of F1, F2, F3 was 298, 
495 and 698nm respectively. The zeta potential of F1, F2 and F3 was -0.27,-0.22and-0.18 
mV respectively The PDI of all formulations was less than 0.5 showing homogenous 
dispersion of nevirapine. The dissolution and diffusion profile of the drug showed that F1 
was found to meet the requirement of not less than 85% drug release at 24h with zero order 
kinetic (r2 0.99). The Cmax, AUC0-24, and AUC0-∞ were significantly (p<0.001) higher than 
that of neviripine alone. Significant change in Tmax of F1 was observed as compared to 
nevirapine alone. The results of the study revealed that nevirapine nanoparticle is beneficial 
in improving the bioavailability of the drug. It can be conclusively stated that nevirapine 
loaded - HSA nanoparticles may be better than the conventional tablet dosage form for the 
treatment of HIV infection.        
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
2.0 INTRODUCTION 
          Viral disease is one of the most prevalent diseases in the modern world. Many 
viruses eventually kill their host cells, resulting in disease and provoking an assault by the 
immune response  of the host. The viral  diseases  are commonly occurring worldwide 
Acquired immunodeficiency  syndrome  (AIDS),   Dengue,  Encephalitis,  Hepatitis,  
Yellofever. Among all the viral diseases AIDS is most dangerous and incurable disease. HIV 
virus comes from the Congo in 1959 and 1960 though genetic studies indicate that it is passed 
into the human population from chimpanzees around fifty years earlier. A recent study states 
that a strain of HIV probably moved from Africa to Haiti and then entered united states 
around 1969. India is one of the largest and most populated countries in the world with over 
one billion in habitants. Of this number it is estimated that around 2.27 million people are 
currently living with HIV, which indicates that there are more people with HIV in india than 
in any other country in the world.1 
Currently HIV is treated with anti HIV drugs such as lamivudine, stavudine and 
zidovudine and nevirapine etc. Nevirapine is particularly indicated in the therapy of HIV as 
non-nucleoside reverse transcriptase inhibitor, and combination of lamivudine, stavudine and 
nevirapine is recommended for effective control of HIV infection. They are available as 
tablet dosage forms commercially. However nevirapine being poorly soluble may pose 
dissolution limited absorption problem resulting in poor bioavailability of the drug and 
therefore difficulty in controlling HIV infection. Different pharmaceutical approaches are 
followed to improve the dissolution of NVP. Solid dispersion of NVP with 
polyvinylpyrolidine (PVP  k30) increase the solubility of nevirapine. 2 
Nanoparticles have become one of the most active areas of research in the field of 
drug delivery due to their ability to deliver drugs to the right place, at appropriate times, and 
in the right dosage. They have received considerable attention over the past 20 years due to 
their advantages compared to other drug delivery system. Nanoparticles can be defined as 
solid micron, colloidal particles ranging in size from 1nm to 1000nm in diameter, generally 
but not necessarily made of natural or synthetic polymers, in which drugs can be adsorbed, 
entrapped, encapsulated or covalently attached and are produced by mechanical or chemical 
means.3 
 
 
A pure anhydrous forn of nevirapine in microspheres was prepared by sublimation 
and condensation of the drug and was reported 30% more solubule than the pure anhydrous 
drug and 140%more soluble than the semihydrate form. These microspheres are suitable for 
formulation into parentral dosage form inhalation therapy and injection.4 Liposomes of 
nevirapine were developed using egg phospholipid to cholesterol ratio at 9:1 which shows a 
prolonged release of NVP upto 1320 min at pH. Nevirapine nanosuspensions for intravenous 
injection was developed for targeting viral resvoirs in body was assessed the in-vitro protein 
absorption was carried out using 2-D PAGE. Bare nanosuspensions and surface modified 
nanosuspension with serum albumin,polysaccharide and PEG were compared regarding there 
protein absorption patterns. Solid lipid nanoparticles and nanostructured liquid carriers 
containing nevirapine were reported. These formulations are coated with formulations human 
serum albumin. An accelerated release of NVP was reported from nanocarriers. When 
incubated with DODAB-stabilised SLNSs, the viability of human brain micro vascular 
endothelial cells (HBMECs) reduced. 5 
         The in-vitro and in-vivo performance of NPs depends on the type of polymers used in 
the development of NPs. Biodegradable polymers are most preferred for NPs because these 
are non toxic easly metabolized and eliminated from the body. Among the biodegradable 
polymers, Albumin NPs have gained considerable attention owing to their high binding 
capacity of various drugs and being well tolerated without any serious side effects. 6 
Human serum albumin (HSA) is a promising bio-macromolecule and draws a great 
attention in both fundamental and applied medication due to its biodegradability, nontoxicity 
nonimmunogenicity and regulatory function. For example, HSA could stabilize the 
ingredients in vaccines and modify the surface of medical devices. In addition the antioxidant 
property of HSA to construct possible innovated structure for therapeutic carriers. In fact 
HSA were used in frabicating albunex and ABI 007 for clinical purpose. 7 
Nanoparticles are prepared by several methods such as a)Amphiphilic 
macromolecules crosslinking b)Polymerization based methods c)Polymer precipitation 
methods d)Ionic gelation method.  
Considering the above factors, it is understood that delivery of nevirapine 
nanoparticles can greatly improve its solubility and improve its bioavailability. Human serum 
albumin (HSA) is a naturally occurring non immunogenic polymer and is considered 
advantageous for development of nevirapine nanoparticles. Desolvation method is easy to 
 
 
follow for the preparation of nanoparticles. Therefore in the present study nevirapine 
nanoparticles was developed using human serum albumin as a polymer by desolvation 
method and the nanoparticles was evaluated for physicochemical, in-vitro and in-vivo release 
characteristics.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.0 REVIEW OF LITERATURE 
Human immunodeficiency virus (HIV) is the causative agent for AIDS. It is a 
sexually transmitted disease. Infection is aided by Langerhans cells in mucosal epithelial 
surfaces and by the  presence of other sexually transmitted diseases that can produce 
mucosal ulceration and inflammation. The CD4+ T-lymphocytes have surface receptors to 
which HIV can attach to promote entry into the cell. The infection extends to lymphoid 
tissues which contain follicular dendritic cells that can become  infected  and provide a 
reservoir for continuing infection of CD4+ T-lymphocytes. When HIV infects a cell, it must 
use its reverse transcriptase enzyme to transcribe its RNA to host cell proviral DNA. It is 
this proviral DNA that directs the cell to produce additional HIV virions which are 
released.8 
EPIDEMIOLGY OF HIV 
The presence of HIV infection among injectors had been reported in 120 of these 
countries. Prevalence estimates of injecting drug use could be ascertained for 61 countries, 
containing 77% of the world’s total population aged 15–64 years. Extrapolated estimates 
suggest that 15·9 million (range 11·0–21·2 million) people might inject drugs worldwide; the 
largest numbers of injectors were found in China, the USA, and Russia, where mid-estimates 
of HIV prevalence among injectors were 12%, 16%, and 37%, rerespectively.HIV prevalence 
among injecting drug users was 20–40% in fi ve countries and over 40% in nine. We estimate 
that, worldwide, about 3·0 million (range 0·8–6·6 million) people who inject drugs might be 
HIV positive. (Bradley m mathews et al) 9 
           Worldwide HIV and AIDS Statistics 
  
 Table 1 
 Estimate
(million)
Range 
(million) 
   People living with HIV/AIDS in 2008 33.4 31.1‐35.8 
Adults living with HIV/AIDS in 2008 31.3 29.2‐33.7 
Women living with HIV/AIDS in 2008 15.7 14.2‐17.2 
Children living with HIV/AIDS in 2008 2.1 1.2‐2.9 
  People newly infected with HIV in 2008 2.7 2.4‐3.0 
Children newly infected with HIV in 2008 0.43 0.24‐0.61 
    AIDS deaths in 2008 2.0 1.7‐2.4 
  
 
 
 The genome of HIV contains only three major genes: env, gag, and pol. These 
genes  direct  the  formation  of  the  basic  components  of  HIV.  The  env  gene  directs 
production of an envelope precursor protein gp160 which undergoes proteolytic cleavage to 
the outer envelope glycoprotein gp120,  which is responsible for tropism to CD4+ 
receptors, and transmembrane glycoprotein gp41, which catalyzes fusion of HIV to the 
target cell's membrane. The gag gene directs formation of the proteins of the matrix p17, 
the  "core"  capsid  p24,  and  the  nucleocapsid  p7.  The  pol  gene  directs  synthesis  of 
important  enzymes  including  reverse  transcriptase  p51  and  p66,  integrase  p32,  and 
protease p11 .10 
 In addition to the CD4 receptor, a coreceptor known as a chemokine is needed for 
HIV infection. Chemokines are cell surface fusion-mediating molecules. Such coreceptors 
include CXCR4 and CCR5. Their presence on cells can aid binding of the HIV 
envelope  glycoprotein gp120, promoting infection. Initial binding of HIV to the CD4 
receptor is mediated by  conformational changes in the gp120 subunit, but such 
conformational changes are not sufficient of fusion. The chemokine receptors produce a 
conformational change in the gp41 subunit which allows fusion of HIV. The differences 
in chemokine coreceptors that are present on a cell also explains how different strains of 
HIV may infect cells selectively. There are strains of HIV known as T-tropic  strains 
which selectively interact with the CXCR4 chemokine coreceptor to infect lymphocytes. 
The  M-tropic strains of HIV interact with the CCR5 chemokine coreceptor to infect 
macrophages. Dual  tropic HIV stains have been identified.11 
MECHANISM  AND TRANSMISSION OF HIV INFECTION 
            HIV primarily infects cells with CD4 cell-surface receptor molecules, using them to 
gain entry  (Figure 1). Many cell types share common epitopes with this protein, though 
CD4 lymphocytes play  a  crucial role. In macrophages and in some other cells lacking 
CD4 receptors, such as fibroblasts, an Fc receptor site or complement receptor site may 
be used instead for entry of HIV. Cells of the mononuclear phagocyte system, principally 
blood monocytes and tissue macrophages, T lymphocytes, B  lymphocytes, natural  killer  
(NK)  lymphocytes,  dendritic  cells  (Langerhans  cells  of  epithelia  and follicular 
dendritic cells in lymph nodes), hematopoietic stem cells, endothelial cells, microglial 
cells  in brain, and gastrointestinal epithelial cells are the primary targets of  HIV infection 
.12 
 
 
  
  
  
  
  
  
  
  
 
              Fig 1 Mechanism of HIV 
 
Human immunodeficiency virus is shown crossing the mucosa of the genital tract to 
infect CD4+ T-lymphocytes. A Langerhans cell in the epithelium is shown in red in this 
diagram.11 
                HIV  is  transmitted  through  direct  contact  of  a  mucous  membrane  or  the 
bloodstream  with a bodily fluid containing HIV, such as blood, semen, vaginal fluid, 
preseminal fluid, and breast milk. This transmission can involve anal, vaginal or oral sex, 
blood transfusion, contaminated hypodermic needles, exchange between mother and baby 
during pregnancy, childbirth, breastfeeding or other exposure to one of the above bodily 
fluids. 
ROLE OF NEVIRAPINE IN HIV INFECTION: 
Nevirapine falls in the non-nucleoside reverse transcriptase inhibitor (NNRTI) class 
of antiretrovirals. Both nucleoside and non-nucleoside RTIs inhibit the same target, the 
reverse transcriptase enzyme, an essential viral enzyme which transcribes viral RNA into 
DNA. Unlike nucleoside RTIs, which bind at the enzyme's active site, NNRTIs bind 
allosterically at a distinct site away from the active site termed the NNRTI pocket. 
Nevirapine is not effective against HIV-2, as the pocket of the HIV-2 reverse transcriptase 
has a different structure, which confers intrinsic resistance to the NNRTI class. 
Nevirapine is a prescription medicine approved by the U.S. Food and Drug 
 
 
Administration (FDA) for the treatment of HIV infection in adults and children. Nevirapine 
is always used in combination with other anti-HIV medicines. It  is a type of anti-HIV 
medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI). NNRTIs work by 
binding to and blocking HIV reverse transcriptase, an HIV enzyme. This prevents HIV from 
replicating and lowers the amount of HIV in the blood. 13 
    Nevirapine does not cure HIV/AIDS. It is not known if nevirapine reduces the risk of 
passing HIV to other people. 
Nevirapine comes in the following forms and strengths: 
• 200-mg immediate-release tablets (brand name: Viramune). 
• 100-mg extended-release tablets (brand name: Viramune XR).  
• 400-mg extended-release tablets (brand name: Viramune XR).  
• 50-mg/5 mL oral suspension (brand name: Viramune).  
          A single dose of nevirapine given to both mother and child reduced the rate of HIV 
transmission by almost 50% compared with a very short course of zidovudine (AZT) 
prophylaxis, in a clinical trial in Uganda. A subsequent study in Thailand showed that 
prophylaxis with single-dose nevirapine in addition to zidovudine is more effective than 
zidovudine alone. These and other trials have led the World Health Organization to 
endorse the use of single-dose nevirapine prophylaxis in many developing world settings 
as a cost-effective way of reducing mother-to-child transmission. However, in the United 
States the Ugandan study was deemed flawed  and as of 2006 the FDA has not approved 
of such nevirapine prophylaxis.14 However,supporters of HIVNET 012 experiment 
argued that the flaws in this experiment were largely due to bureaucratic incompetence, 
while the findings regarding the safety and efficacy of single-dose nevirapine from this 
study were scientifically solid and too important to discard. Moreover, it was argued that 
holding African researchers who operated under resource-poor situations to the same 
moral and procedural standards to their Western counterparts was unrealistic, and would 
further marginalize African researchers' role in the science community and impede the 
progress of African science. Another clinical trial, Using Nevirapine to Prevent Mother-
to-Child HIV Transmission During Breastfeeding is scheduled for completion in March 
2011.15 
 
 
A major concern with this approach is that NNRTI resistance mutations are commonly 
observed in both mothers and infants after single-dose nevirapine , and may compromise the 
response to future NNRTI-containing regimens. A short course of maternal 
zidovudine/lamivudine is recommended by the U.S. Public Health Service Task Force to 
reduce this risk. 
APPROACHES TO IMPROVE BIOAVAILABILITY OF NEVIRAPINE: 
        The present work was to improve the solubility of Nevirapine by solid dispersion 
techniques using Polyvinylpyrrolidone K 30 (PVP K 30) as carrier. The Solid dispersion was 
prepared by physical mixing, solvent evaporation and kneading method. The interaction of 
the Nevirapine with PVP K 30 was evaluated by the Fourier transform infrared (FTIR) 
spectroscopy; Differential scanning Calorimetry (DSC), X-ray diffraction patterns (XRD). 
The results from the FTIR and XRD analyses showed that Solid dispersion might exist in the 
amorphous form. A DSC result showed that the sharp melting point was completely 
disappeared suggesting that the Nevirapine molecularly dispersed in an amorphous form. 
Saturation solubility and dissolution studies indicate that dissolution rate was remarkably 
increased in Solid dispersion as compared to the physical mixture and drug alone. In 
conclusion PVP K 30 can be a well utilized to increase the solubility of poorly water soluble 
drugs. ( Ahire B. R. et al 2010) 4 
This invention entails the preparation of very pure nano-and microspheres , measuring 
approximately 0,5-4 μm of a novel form of nevirapine. The microspheres are prepared 
without the use of any excipients or other carrier substances. The method involves the 
sublimation and condensation of the nevirapine raw material without any carrier or 
excipients,rendering a pure anhydrous form of nevirapine. This new form was found at least 
30% more soluble than the anhydrous form and 140% more soluble than the hemihydrate 
form. The small size of the new form’s particles (0,5-4  μm) majes them suitable for suitable 
for formulation into parentral dosage forms, making inhalation therapy and injection possible. 
(Rudi Van Der Walt et al) 16 
In the present study liposomes of uniform diameters were prepared using thin film 
hydration and extrusion technique and a hydrophobic non-nucleoside reverse trascriptase 
inhibitor, nevirapine was successfully encapsulated in the liposomes. The best encapsulation 
was observed at an egg phospholipid to cholesterol ratio og 9:1 which also showed a 
prolonged rerelease of nevirapine up to 1320 minutes at physiological ph. Presence of 
 
 
proteins in the medium and external stimuli like low frequency ultrasound was found to 
enhaance the rate of drug release. The use of ultrasound leading to higher magnitude of drug 
release thus points to a potentially novel approach towards anti-retroviral therapy. Presence 
of cholesterol in the liposomes offers stability against fluidizing actio of proteins without 
preventing the disruption of the liposomal architecture by ultrasound. (Lakshmi N Ramana 
et al)5 
NANOTECHNOLOGY 
Nanotechnology, the term derived from the Greek word Nano, meaning dwarf, applies 
the principles of engineering, electronics, physical and material science, and manufacturing at a 
molecular or submicron level. The materials at nanoscale could be a device or a system or these 
could be supramolecular structures, complexes or composites. 
An early promoter of nanotechnology, Albert Franks, defined it as ‘that area of 
science and technology where dimensions and tolerances are in the range of 0.1nm to 100nm’. 
Nano technology is expected to make significant advances in the mainstream biomedical 
applications, including in the areas of gene therapy, drug delivery, imaging, and novel drug 
discovery techniques. 17 
 Nanotechnology is hailed as a new generation of technology with the potential to 
revolutionise many facets of the world we live in. This includes virtually all aspects of daily 
life, including health and health care, the manufacturing and use of materials and equipment, 
the environment and protection thereof. It is said to be able to massively increase 
manufacturing production at significantly reduced costs. Products of nanotechnology will be 
smaller, cheaper, lighter yet more functional and require less energy and fewer raw materials to 
manufacture. However, the ‘revolution’ will not happen overnight and very large investments 
in research and development will be required in the process. 
 
Nanotechnology can be defined as having the following features 
¾ It involves research and technology development at the 1 nm–100 nm range 
¾ It creates and uses structures that have novel properties because of their small Size 
¾ It builds on the ability to control or manipulate at the atomic and molecular scale 
 
 
At the nano-scale the interactions and physics between atoms display ‘exotic’ 
properties that are absent at larger scale because at this level atoms leave the realm of classical 
physical properties behind and enter the realm of quantum mechanics. 
Nanotechnology includes a bewildering array of activities including: molecular 
manufacturing, supramolecular and self assembly/organization; biomimicry; nanoparticles (e.g. 
Bucky balls and carbon nano tubes), nanospheres, nano cups and nanorods; nanobots 
(nanorobots); colloids, micelles, vesicles and nano-emulsions; clathrate complexes and 
intercalation compounds. 
The National Science Foundation in the USA predicts that the global marketplace for 
goods and services using nanotechnologies will grow to $1 trillion by 2015, and there are 
already over 500products being sold that claim they are made with nanoscale or engineered 
Nanomaterials. These include products like self-cleaning windows, automobile paint, 
sunscreens, and tennis rackets. In the future, a marriage of nano- and biotechnology will likely 
create a whole new generation of drugs, biomedical devices, and other solutions to some of our 
most challenging medical problems18. 
Nanotechnology in drug delivery: 
The development of delivery systems for small molecules, proteins and DNAhas been 
impacted to an enormous degree over the past decade by nanotechnology, and has led to the 
development of entirely new and somewhat unpredicted fields. For the pharmaceutical 
industry, novel drug delivery technologies represent a strategic tool for expanding drug 
markets. The technology can address issues associated with current pharmaceuticals such as 
extending product life (line extension), or can add to their performance and acceptability, either 
by increasing efficacy or improving safety and patient compliance19. This technology is 
permitting the delivery of drugs that are highly water- insoluble or unstable in the biological 
environment. Advantages of Nano sizing of drugs has the potential to: Increase surface area, 
enhance solubility, increase rate of dissolution, increase oral bioavailability, more rapid onset 
of therapeutic action, decrease the dose needed, decrease fed/fasted variability and decrease 
patient to patient variability. 
In recent trend, Nano drug delivery may occur through gold nanospheres and rods, 
nanowires, nanotriangles, nanostars, nanocubes, and nanorice. The size of these nano 
configurations varies from 1 to 100 nm. Nanoplatforms include organic nanostructures, 
polymeric nanoparticles, lipid systems-liposomes, self assemblies-micelles, dendrimers, and 
 
 
carbon nanostructure-nanotubes. Inorganic nanostructures include metal nanoparticles and 
nanoshells, silicon nanostructure, nanocrystals, and quantum dots. Hybrid nanostructures, 
combining two to three of those previous listed can also be produced. Studies were described in 
which polymeric nanoparticles were used for tumor-targeted deliver. Gelatin-based engineered 
nanoparticles have been used for gene delivery and multifunctional nanoemulsions for oral and 
intravenous delivery. Gadolinium-loaded nanoemulsion has been used in animals for brain 
imaging, and this technology could easily be used for imaging within the eye to observe the 
results of various drug delivery modalities. 
 
The benefits of Nanotechnology are: 
• The lifespan of the blockbuster drugs can be resurrected by reformulating the 
• drugs through novel drug delivery system. 
• The effective patent protection can be enhanced. 
• Drug delivery formulation involves low cost research compared to that for the 
• discovery of new molecules. 
• Minimizing use of expensive drugs would reduce the cost of the product. 
 
  NANOPARTICLES 
Nanoparticles are solid colloidal particles with diameters ranging from 1-1000 nm. 
They consist of macromolecular materials and can be used therapeutically as adjuvant in 
vaccines or drug carriers, in which the active ingredient is dissolved, entrapped, encapsulated, 
adsorbed or chemically attached. Polymers used to form nanoparticles can be both synthetic 
and natural polymers. There are two types of nanoparticles depending on the preparation 
process nanospheres and nanocapsules. Nanospheres have a monolithic-type structure 
(matrix) in which drugs are dispersed or adsorbed on to their surfaces. Nanocapsules exhibit a 
membrane-wall structure and drugs are entrapped in the core or adsorbed on to their exterior 
.The term “nanoparticles” is adopted because it is often very difficult to unambiguously 
establish whether these particles are of a matrix or a membrane type.20 In recent years, 
biodegradable polymeric nanoparticles, particularly those coated with hydrophilic polymer 
such as poly (ethylene glycol) (PEG) known as long-circulating particles, have been used as 
potential drug delivery devices because of their ability to circulate for a prolonged period 
 
 
time, target a particular organ, as carriers of DNA in gene therapy, and their ability to deliver 
proteins, peptides and genes.21  
   The major goals in designing nanoparticles as a delivery system are to control particle 
size, surface properties and release of pharmacologically active agents in order to achieve the 
site-specific action of the drug at the therapeutically optimal rate and dose regimen. Though 
liposomes have been used as potential carriers with unique advantages including protecting 
drugs from degradation, targeting to site of action and reduction toxicity or side effects, their 
applications are limited due to inherent problems such as low encapsulation efficiency, rapid 
leakage of water-soluble drug in the presence of blood components and poor storage stability. 
On the other hand, polymeric nanoparticles offer some specific advantages over liposomes. For 
instance, they help to increase the stability of drugs/proteins and possess useful controlled 
release properties22   
The Advantages of using nanoparticles as a drug delivery system include the following 
¾ Particle size and surface characteristics of nanoparticles can be easily manipulated to 
achieve both passive and active drug targeting after parenteral administration.  
¾ They control and sustain release of the drug during the transportation and at the site of 
localization, altering organ distribution of the drug and subsequent clearance of the 
drug so as to achieve increase in drug therapeutic efficacy and reduction in side 
effects.  
¾ Controlled release and particle degradation characteristics can be readily modulated 
by the choice of matrix constituents. Drug loading is relatively high and drugs can be 
incorporated into the systems without any chemical reaction; this is an important 
factor for preserving the drug activity.  
¾ Site-specific targeting can be achieved by attaching targeting ligands to surface of 
particles or use of magnetic guidance. 
¾ The system can be used for various routes of administration including oral, nasal, 
parenteral, intra-ocular etc.  
 
 In spite of these advantages, nanoparticles do have limitations. For example, their 
small size and large surface area can lead to particle particle aggregation, making physical 
handling of nanoparticles difficult in liquid and dry forms. In addition, small particles size and 
large surface area readily result in limited drug loading and burst release. These practical 
 
 
problems have to be overcome before nanoparticles can be used clinically or made 
commercially available. 
Related works on nanoparticles with anti hiv drugs: 
In the present study, an attempt was made to develop nanoparticulate delivery 
system for highly water soluble drug lamivudine. Chitosan  nanoparticles  of  drug  
lamivudine  were  prepared  by  ionic  gelation technique.  The  method was able to 
produce discrete, free flowing and uniform sized particles. All the  formulations  showed  
high  process  yield  and  drug  loading  capacity. Among the different batches, 
Formulation F1 (drug polymer ratio 1:1) was selected as the ideal formulation, after 
considering their better drug loading capacity, and in vitro drug release. Based on the 
observations, it can be concluded that the formulated nanoparticulate delivery  system  of 
highly water soluble drug lamivudine using widely accepted and physiologically safe 
polymer was capable of exhibiting sustained release properties for a period of 24 h. They 
are thus may be reduce frequency of dosing, thereby minimizing the occurrence of side 
effects, improve bioavailability and increase the effectiveness of the drug.  ( Dhanush et 
al ) 23 
 
Albumin nanoparticles of anti viral drug azidothymidine were prepared and evaluated 
for brain specific delivery after intravenous administration. Long circulatory 
polyethyleneglycolated (PEGylated) albumin nanoparticles of azidothymidine were prepared 
by ultra-emulsification method using chemical cross linking by glutaraldehyde. Surface of 
PEGylated nanoparticles was modified by anchoring teansferrin as a ligand for brain 
targeting. Fluorescence studies revealed the enhanced uptake of transferring-anchored 
nanoparticles in brain tissue when compared with unmodified nanoparticles. A significant 
enhancement of brain localization of azidothymidine was observed for transferring anchored 
PEGylated albumin nanoparticles  (vivek m et al.,).24 
 
            In the study of nevirapine nanosuspensions were prepared by high-presssure 
homogenization characterized. A crystalline NS of nevirapine for intravenous injection was 
developed assessed regarding its  targeting potential to viral reservoirs in body .To determine 
the intereactions of the nanocrystals with proteins,in vitro protein absorption studies in 
plasma were carried out using 2-D PAGE. The in vitro protein rejecting and accepting 
 
 
proteins were studied as a function of stabilizer of the nanocrystals Bare NS and surface 
modified NS (eg serum albumin, polysaccharide and PEG) were compared regarding their 
protein absorption patterns.     (Ranjitha shegokar et al 2011 ) 25 
Solid lipid nanoparticles(SLNs) and nanostructured lipid carriers(NLCs) coated with 
human serum albumin(HSA) were fabricated for formulating nevirapine(NVP). Here NLCs 
contained low melting point oleic acid(OA) in the internal liquid phase.The results revealed 
that the two nanoparticles were uniformly distributed with th average diameter ranging from 
145 to 180nm. The surface HSA neutralized the positive charge of dimethyldioctadecyl 
ammonium bromide (DODAB) on SLNs and NLCs and reduced their zeta potential. In a 
fixed ratio of solid lipids, SLNs entrapped more NVP than NLC. The incorporation of OA 
also reduced the thermal resistance of NLCs and accelerated the release of NVP from the 
nanocarriers. When with DODAB-stabilized SLNs, the viability of human brain 
microvascular endothelial cells reduced. However the surface HSA increased the viability of 
HBMECs about 10% when the cancentration of SLNs was higher than 0.8mg/ml. HSA 
grafted SLNs and NLCs can be effective formulations in the delivery of NVP for viral 
therapy. (Yung-chih kuo et al 2010) 26 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 
POLYMERS USED FOR THE PREPARATION OF NANOPARTICLES27 
 
 
 
Polymer use Technique Candidate drug 
Hydrophilic 
Albumin, gelatin 
 
 
 
 
Alginate, chitosan 
Dextarn 
 
Hydrophobic 
Poly(alkylcyanoacrylates) 
 
 
 
Polyesters 
Poly (lactic acid), poly 
(lactide-co-glycolide), poly 
(e-cprolactone) 
 
Heat denaturation and cross-
linking in w/o emulsion 
Desolvation and cross-linking 
in aqueous medium 
 
Cross-lining in aqueous 
medium polymer precipitation 
in an organic solvent 
 
Emulsion polymerization 
Interfacial o/w polymerization 
 
Solvent extraction-evaporation 
 
Solvent displacement 
Salting out 
 
Hydrophilic 
 
Hydrophobic and 
protein affinity 
 
Hydrophilic 
Hydrophilic 
 
 
Hydrophilic 
Hydrophobic 
 
Hydrophilic& 
Hydrophobic 
Soluble in polar solvent 
Soluble in polar solvent
 
 
These methodologies are conveniently classified as follow 
1) Amphiphilic macromolecules cross-linking 
a) Heat cross-linking 
b) Chemical cross-linking 
2) Polymerization based methods 
a) Polymerization based methods 
b) Emulsion (micellar) polymerization 
c) Dispersion polymerization 
d) Interfacial condensation polymerization 
e) Interfacial complexation 
3) Polymer precipitation methods 
a) Solvent extraction/evaporation 
b) Solvent displacement (nanoprecipitation) 
c) Salting out 
4) Ionic gelation method 
Nanoparticles can be prepared from a variety of materials such as proteins, 
polysaccharides and synthetic polymers. The selection of matrix materials is dependent on 
many factors including28 
a) Size of nanoparticles required. 
b) Inherent properties of the drug e.g., aqueous solubility and stability. 
c) Surface characteristics such as charge and permeability. 
d) Degree of biodegradability, biocompatibility and toxicity. 
e) Drug release profile desired and 
f) Antigencity of the final product. 
Nanoparticles have been prepared most frequency by three methods. 
1) Dispersion of preformed polymers. 
2) Polymerization of monomers; and 
3) Coacervation. 
How ever other methods such as superficial fluid technology and particle replication 
in non-wetting templates have also been described in the literature for production of 
nanoparticles. The latter was claimed to have absolute control of particle size, shape and 
composition, which could set an example for the future mass production of nanoparticles in 
industry. Dispersion of preformed polymers is a common technique used to prepare 
 
 
biodegradable nanoparticles from poly (lactic acid) (PLA); poly (D, L-glycoside), PLG; poly 
(D, L-lactide-co-glycolide) (PCA) 21. This technique can be used in various ways as 
described below. 
  Solvent evaporation method: 
In this method, the polymer is dissolved in an organic solvent such as 
dichloromethane, chloroform or ethyl acetate, which is also used as the solvent for dissolving 
the hydrophobic drug. The mixture of polymer and drug solution is then emulsified in an 
aqueous solution containing a surfactant or emulsifying agent to form oil in water (o/w) 
emulsion. After the formation of stable emulsion, the organic solvent is evaporated either by 
reducing the pressure or by continuous stirring. Particle size was found to be reducing the 
pressure or by continuous stirring. Particle size was found to influence by the type and 
concentrations of stabilizer, homogenizer speed and polymer concentration. In order to 
produce small particle size, often a high-speed homogenization or ultrasonication may be 
employed.29 
Spontaneous emulsification or solvent diffusion method: 
This is a modified version of solvent evaporation method19. In this method, the water 
miscible solvent along with a small amount of the water immiscible organic solvent is used as 
an oil phase. Due to the spontaneous diffusion of solvents an interfacial turbulence is created 
between the two phases leading to the formation of small particles. As the concentration of 
water miscible solvent increases, a decrease in the size of particle can be achieved. Both 
solvent evaporation and solvent diffusion methods can be used for hydrophobic or 
hydrophilic drugs. In the case of hydrophilic drug, a multiple w/o/w emulsion needs to be 
aqueous phase.30 
Polymerization method 
In this method, monomers are polymerized to form nanoparticles in an aqueous 
solution. Drug is incorporated either by being dissolved in the polymerization medium or by 
adsorption onto the nanoparticles after polymerization completed. The nanoparticle 
suspension is then purified to remove various stabilizers and surfactants employed for 
polymerization by ultracentrifugation and re-suspending the particles in an isotonic 
surfactant-free medium. This technique has been reported for making polybutylcyanoacrylate 
or poly (alkylcyanoacrylate) nanoparticles. Nanocapsules formation and their particle size 
depend on the concentration of the surfactants and stabilizers used.31,32 
 
 
 
 
Cocervation or ionic gelation method 
Much research has been focused on the preparation of nanoparticles using 
biodegradable hydrophilic polymers such as Chitosan, gelatin and sodium alginate. Calvo and 
co-workers developed a method for preparing hydrophilic Chitosan nanoparticles by ionic 
gelation. The method involves a mixture of two aqueous phases, of which one is the polymer 
chitosan, a di-block co-polymer ethylene oxide or propylene oxide (PEOPPO) and the other 
is a polyanions sodium tripolyphosphate. In this method, positively charged amino group of 
chitosan interacts with negative charged tripolyphosphate to form coacervates with a size in 
the range of nanometer. Coacervates are formed as a result of electrostatic interaction 
between two aqueous phases, whereas, ionic gelation involves the material undergoing 
transition from liquid to gel due to ionic interaction conditions at room temperature.31 
Production of nanoparticles using superficial fluid technology33 
Conventional methods such a solvent extraction-evaporation, solvent diffusion and 
organic phase separation methods require the use of organic solvents which are hazardous to 
the environment as well as to physiological systems. Therefore, the superficial fluid technology 
has been investigated as an alternative to prepare biodegradable micro and nanoparticles 
because supercritical fluids are environmentally safe. 
A superficial fluid can be generally defined as a solvent at a temperature above its 
critical temperature, at which the fluid remains a single phase regardless of pressure. 
Supercritical CO2 (SC CO2) is the most widely used supercritical fluid because of its mild 
critical conditions (Tc = 31.10C, Pc = 73.8 bars), non-toxicity, non-inflammability, and low 
price. The most common techniques involving supercritical fluids are supercritical anti-solvent 
(SAS) and rapid expansion of critical solution. The process of SAS employs a liquid solvent, 
e.g. methanol, which is completely miscible with the supercritical fluid to dissolve the solute to 
be micronized; at the process conditions, because the solute is insoluble in the supercritical 
fluid, the extract of the liquid solvent by supercritical fluid leads to the instantaneous 
precipitation of the solute, resulting the formation of nanoparticles. Thote and gupta (2005) 
reported the use of a modified SAS method for formation of hydrophilic drug dexamethasone 
phosphate drug nanoparticles for micro encapsulation purposes. 
Polyelectrolyte complex (PEC) 34 
Polyelectrolyte complex or self assemble polyelectrolyte is a term to describe 
complexes formed by self-assembly of the cationic charged polymer and plasmid DNA. 
 
 
Mechanism of PEC formation involves charge neutralization between cationic polymer and 
DNA leading to a fall in hydrophilicity as the polyelectrolyte component self assembly. Several 
cationic polymers (i.e. gelatin, polyethylenimine) also possess this property. Generally, this 
technique offers simple and mild preparation method without harsh conditions involved. The 
nanoparticles spontaneously formed after addition of DNA solution into Chitosan dissolved in 
acetic acid solution, under mechanical stirring at or under room temperature (Erbacher et al., 
1998). The complexes size can be varied from 50 nm to 700 nm. 
Microemulsion method35 
Chitosan NP prepared by microemulsion technique was first developed by Maitra et 
1999).This technique is based on formation of chitosan NP in the aqueous core of reverse 
micellar droplets and subsequently cross-linked through glutaraldehyde. In this method, a 
surfactant was dissolved in N-hexane. Then, chitosan in acetic solution and glutaraldehyde 
were added to surfactant/hexane mixture under continuous stirring at room temperature. 
Nanoparticles were formed in the presence of surfactant. The system was stirred overnight to 
complete the cross-linking process, which the free amine groups of chitosan conjugate with 
glutaraldehyde. The organic solvent is then removed by evaporation under low pressure. The 
yields obtained were the cross-linked chitosan NP and excess surfactant. The excess surfactant 
was then removed by precipitate with CaCl2 and then the precipitant was removed by 
centrifugation. The final nanoparticles suspension was dialyzed before Lyophilization. This 
technique offers a narrow size distribution of less than 100 nm and the particle size can be 
controlled by varying the amount of glutaraldehyde that alters the degree of cross-linking. 
Nevertheless, some disadvantages exist such as the use of organic solvent, time-consuming 
preparation process, and complexity in the washing step. 
Freeze drying of nanoparticles36 
 Protective excipients, such as carbohydrates, are widely used in freeze-drying to 
ensure redispersibility and to avoid aggregation or size changes of nanoparticles50. Glucose 
and lactose were evaluated as cryo- and lyo protectants for the L- PLA nanoparticles because 
these nanoparticles could not survive during the drying process without protectants. Even the 
smallest tested amount of glucose (weight ratio glucose: nanoparticles 1:4) was found to 
protect the nanoparticles, although the appearance of the dried material was translucent and 
sticky, and its redispersibility was poor. When lactose was used as a protectant, it enhanced 
the appearance of the cake (the dried material) as a white powder, eligible for a freeze-dried 
 
 
formulation. Redispersion of the nanoparticle was possible, but as a form of visible 
aggregates. Further freeze-thawing experiments revealed that already the freezing step (with 
lactose) destroyed the particles. Next, the two carbohydrates were used together to combine 
the cryoprotective functionality of glucose and the lyoprotective functionality of lactose. The 
best result, prolonged Tyndall effect (opalescence in the dispersion) after redispersion of the 
dried formulation and good quality nanoparticles were obtained, when the amount of lactose 
was double the amount of glucose. The weight ratios of glucose and lactose to the 
nanoparticles were 1:2 and 1:1, respectively. Additionally, when an extra stabilizer, Tween 
80, was used during the nanoparticle preparation or during the redispersion, the freeze-dried 
cake could be redispersed more easily with increased stability (prolonged Tyndall effect). 
The good cryoprotective results with glucose probably arise from its ability to bind 
water molecules to the amorphous phase which it forms during the freezing step. Part of the 
water in the frozen glucose remained non-frozen (even 32% w/w). That water acted as a 
plasticizer and as a spacing matrix reducing the pressure of ice crystals against the 
nanoparticles and preventing harmful aggregation caused by freeze concentration, respectively. 
At the same time, insufficient cryoprotective function of lactose derived most likely from its 
lower water binding activity. However, as a combination with glucose, lactose reduced the 
amount of water to a level where the interaction of glucose with water was reduced and, thus, 
the formation of ice crystal was slightly promoted. This enabled sufficient evaporation of water 
during the drying and formation of a proper cake. Tween 80 improved the freeze-drying result 
as it acted as a steric stabilizer and increased the hydrophilicity of the nanoparticles. A 
hydrophilic surface enhances the redispersion properties of the freeze-dried nanoparticles 37,38. 
 
This technique involves the freezing of the nanoparticle suspension and subsequent 
sublimation of its water content under reduced pressure to get a free flowing powdered 
material following advantages are cited for the freeze drying of nanopartilces29: 
• Prevention from degradation and/or solubilization of the polymer. 
• Prevention from drug leakage, drug desorption and/or drug degradation.  
• Easy to handle and store and helps in long-term prevention/conservation of 
nanoparticles.  
Readily dispersible in water without modification in their physicochemical properties. 
 
 
Criteria for ideal polymeric carriers for nanoparticles & nanoparticle delivery systems39 
Polymeric carriers 
¾  Easy to synthesize and characterize 
¾  Inexpensive 
¾  Biocompatible 
¾  Biodegradable 
¾  Non-immunogenic 
¾  Non-toxic 
¾  Water soluble 
 
Nanoparticle delivery systems 
¾  Simple and inexpensive to manufacture and scale-up 
¾  No heat, high shear forces or organic solvents involved in their preparation   process. 
¾  Reproducible and stable 
¾  Applicable to a broad category of drugs; small molecules, proteins and 
polynucleotides 
¾  Ability to lyophilize 
¾  Stable after administration 
¾  Non-toxic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 
CHARACTERISTICS OF NANOPARTICLES ON DRUG DELIVERY 
DIFFERENT PARAMETERS AND CHARACTERIZATON METHODS OF 
NANOPATICLES29 
 
 
Parameter Characterization method 
Particle size and distribution 
Photo correlation spectroscopy (PCS) 
Laser defractometry 
Transmission electron microscopy(TEM) 
Scanning electron microscopy(SEM) 
Mercury porositometry 
Charge determination Laser Doppler anemometry 
Zeta potentiometer 
Surface hydrophobicity 
Water Doppler Anemometry 
Rose Bengal (dye) binding 
Hydrophobic interaction chromatography 
X-ray photoelectron spectroscopy 
Chemical analysis of surface Static secondary ion mass spectroscopy 
Carrier-drug interaction Differential scanning calorimetry (DSC) 
Nanoparticles dispersion stability Critical flocculation temperature (CFT) 
Release profile 
In vitro release characteristics under 
physiologic and sink conditions 
Drug stability 
Bioassay of drug extracted from 
nanoparticles chemical analysis of drug 
 
 
Particle Size 
Particle size and size distribution are the most important characteristics of nanoparticle 
systems. They determine the in vivo distribution, biological fate and targeting ability of 
nanoparticle systems. In addition they can also influence the drug loading, drug release and 
stability of nanoparticles. 
Many studies have demonstrated that nanoparticles of sub-micron size have a number of 
advantages over microparticles as a drug delivery system44. Generally nanoparticles have 
relatively higher intracellular uptake compared to microparticles and available to wider range 
of biological targets due to their small size and relative mobility.100nm nanoparticles had a 2.5 
fold greater uptake than 1µm microparticles and 6 fold greater uptakes than 10µm 
microparticles in a CACO-2 cell line (Desai et al 1996). In a subsequent study, the 
nanoparticles penetrated through out the sub mucosal layers in a rat in situ intestinal loop 
model, while microparticles were predominantly localized in the epithelial lining. It was also 
reported that nanoparticles can cross the blood-brain barrier following the opening of tight 
junctions by hyper osmotic mannitol, which may provide sustained delivery of therapeutic 
agents for difficult-to-treat diseases like brain tumors. Tween 80 coated nanoparticles have 
been showed to cross the blood-brain barrier. In some cell lines, only submicron nanoparticles 
can be taken up effectively but not the larger size microparticles. The recent literature shows 
ophthalmic nanosuspension that proves to be boon for drugs that exhibit poor soluble in 
lachrymal fluid. 
 
Drug release is affected by particle size. Smaller particles have larger surface area; 
therefore, most of the drug associated would be at or near the particle surface, leading to fast 
drug release. The particle surface, leading to fast drug release. Whereas, larger particles have 
large cores which allow more drug to be encapsulated and slowly diffuse out40. 
Currently, the fastest and most routine method of determining particle size is by photon-
correlation spectroscopy or dynamic light scattering. Photon-correlation spectroscopy requires 
the viscosity of the medium to be known and determines the diameter of the particle by 
Brownian motion and light scattering properties41. The results obtained by photon-correlation 
spectroscopy are usually verified by scanning or transmission electron microscopy (SEM or 
TEM). 
 
 
Surface Properties of Nanoparticles 
When nanoparticles were administered intravenously, they are easily recognized by the 
body immune systems, and are then cleared by phagocytes from the circulation. A part from the 
size of nanoparticles, their surface hydrophobicity determines the amount of adsorbed blood 
components, mainly proteins. This is turn influences the in vivo fate of nanoparticles. Binding 
of these opsonins onto the surface of nanoparticles called opsonization acts as a bridge between 
nanoparticles and phagocytes. The association of a drug to conventional carriers leads to 
modification of the drug biodistribution profile, as it is mainly delivered to the mononuclear 
phagocytes system such as liver, spleen, lungs and bone marrow. Indeed, once in the blood 
stream, surface non-modified nanoparticles are rapidly opsonized and massively cleared by the 
macrophages of mononuclear phagocytes system rich organs. Generally, it is IgG, compliment 
C3 components that are used for recognition of foreign substances, especially foreign 
macromolecules. 
 
Hence, to increase the likelihood of the success in drug targeting by nanoparticles, it is 
necessary to minimize the opsonized and to prolong the circulation of nanoparticles in vivo. 
This can be achieved by surface coating of nanoparticles with biodegradable copolymers with 
hydrophilic segments such as polyethylene glycol (PEG) Polyethylene oxide, polyoxamer, 
poloxamine and polysorbate 80 (Tween 80). 
 
The zeta potential of a nanoparticle is commonly used to characterize the surface charge 
property of nanoparticles42. It reflects the electrical potential of particles and is influenced by 
the composition of the particle and the medium in which it is dispersed. Nanoparticles with a 
zeta potential above (+/-) 30 mV have been shown to be stable in suspension, as the surface 
charge prevents aggregation of the particles. The zeta potential can also be used to determine 
whether a charged active material is encapsulated within the centre of the nanocapsule or 
adsorbed onto the surface.  
 
 
 
 
 
Drug-polymer interactions43 
Drug loading can be performed during the preparation of nanoparticles or by 
adsorbing/absorbing in preformed particles. Within the particle-forming polymer, drug can be 
present as a solid solution (individual drug molecules) or as a solid dispersion 
(amorphous/crystalline drug). It can be adsorbed on the particle surface or bound chemically 
within the nanoparticles .The preparation process can also modify the crystal structure of the 
drug. The polymer is usually amorphous or semi-crystalline. Differential scanning calorimetry 
(DSC), (powder) x-ray diffractometry (XRPD) and FTIR are commonly used techniques to 
reveal the physicochemical state and possible interactions of the drug and the polymer in 
pharmaceutical micro- and nanoparticles. Polymer MW is determined e.g. by size exclusion 
chromatography (SEC) the term gel permeation chromatography (GPC) is interchangeably 
used. 
 
 DSC detects phase transitions such as glass transition, (exothermic) crystallization and 
(endothermic) melting: the nanoparticle sample is heated and changes in heat flow, compared 
to reference, are registered .Crystallinity/amorphicity properties are obtained from XRPD 
analysis when diffraction pattern of the x-ray from the sample is determined as a function of 
scattering angle.. In FTIR, a vibrational spectrum, characteristics for a given crystal structure, is 
obtained. 
Absence of the drug melting peak and diffraction peaks of the crystal structure of the 
drug in DSC thermo gram and XRPD pattern, respectively, are usually signs of amorphous or 
molecularly dispersed drug within the polymer .It can also indicate that the amount of drug is 
lower than the detection limit of the instrument .Drug polymer interactions (e.g. plasticizing 
effect of drug on polymer) or polymorph change of the drug can be detected as peak shifts in 
DSC thermogram, band shifts in FTIR spectra or as new reflections in XRPD pattern. 
Correspondingly, smoothened XRPD pattern, increased cold crystallization exotherms (DSC) 
or some band shifts to higher wave numbers (FTIR) indicate increased amorphicity of the 
polymer. 
 
 
 
 
 
Drug loading44 
Ideally, a successful nanoparticulate system should have a high drug-loading capacity 
thereby reduce the quantity of matrix materials for administration. Drug loading can be done by 
two methods:  
• Incorporating at the time of nanoparticles production (incorporation method)  
• Absorbing the drug after formation of nanoparticles by incubating the carrier with a 
concentrated drug solution (adsorption /absorption technique). Drug loading and entrapment 
efficiency very much depend on the solid-state drug solubility in matrix material or polymer 
(solid dissolution or dispersion), which is related to the polymer composition, the molecular 
weight, the drug polymer interaction and the presence of end functional groups (ester or 
carboxyl). The PEG moiety has no or little effect on drug loading. The macromolecule or 
protein shows greatest loading efficiency when it is loaded at or near its isoelectric point when 
it has minimum solubility and maximum adsorption  For small molecules, studies show the use 
of ionic interaction between the drug and matrix materials can be a very effective way to 
increase the drug loading.45,46 
In-vitro Drug release44 
To develop a successful nanoparticulate system, both drug release and polymer 
biodegradation are important consideration factors. In general, drug release rate depends on: (1) 
solubility of drug; (2) desorption of the surface bound/adsorbed drug; (3) drug diffusion 
through the nanoparticle matrix; (4) nanoparticle matrix erosion/degradation; and (5) 
combination of erosion/diffusion process. Thus solubility, diffusion and biodegradation of the 
matrix materials govern the release process.  
In the case of nanospheres, where the drug is uniformly distributed, the release occurs 
by diffusion or erosion of the matrix under sink conditions. If the diffusion of the drug is faster 
than matrix erosion, the mechanism of release is largely controlled by a diffusion process. The 
rapid initial release or ‘burst’ is mainly attributed to weakly bound or adsorbed drug to the 
large surface of nanoparticles47. It is evident that the method of incorporation has an effect on 
release profile. If the drug is loaded by incorporation method, the system has a relatively small 
burst effect and better sustained release characteristics. If the nanoparticle is coated by 
polymer, the release is then controlled by diffusion of the drug from the core across the 
polymeric membrane. The membrane coating acts as a barrier to release, therefore, the 
 
 
solubility and diffusivity of drug in polymer membrane becomes determining factor in drug 
release. Furthermore release rate can also be affected by ionic interaction between the drug and 
addition of auxillary ingredients. When the drug is involved in interaction with auxillary 
ingredients to form a less water soluble complex, then the drug release can be very slow with 
almost no burst release effect; whereas if the addition of auxillary ingredients e.g., addition of 
ethylene oxide-propylene oxide block copolymer (PEO-PPO) to chitosan, reduces the 
interaction of the model drug bovine serum albumin (BSA) with the matrix material (chitosan) 
due to competitive electrostatic interaction of PEO-PPO with chitosan, then an increase in drug 
release could be observed48. 
 Various methods which can be used to study the in vitro release of the drug are: (1) 
side-by-side diffusion cells with artificial or biological membranes; (2) dialysis bag diffusion 
technique; (3) reverse dialysis bag technique; (4) agitation followed by 
ultracentrifugation/centrifugation; (5) Ultra-filtration or centrifugal ultra-filtration techniques. 
Usually the release study is carried out by controlled agitation followed by centrifugation. Due 
to the time-consuming nature and technical difficulties encountered in the separation of 
nanoparticles from release media, the dialysis technique is generally preferred.  
. 
 
 
 
      4.0 PROFILES 
4.1 DRUG PROFILE  
NEVIRAPINE 51,52 : 
Category: Anti retroviral agent 
Empirical formula: C15H14N4O 
Molecular weight: 266.3 
Physical properties: White to all most white crystalline powder 
Solubility: Practically insoluble in water. Sparingly soluble or slightly soluble in 
dichloromethane. Slightly soluble in methyl alcohol. 
Chemical structure: 
                                               
11‐cyclopropyl‐4‐methyl‐5,11‐dihydro‐6H‐dipyrido[3,2‐b:2,3‐e][1,4]diazepin‐6‐one. 
Mechanism of action: 
Nevirapine diffuses into the cell and binds to reverse transcriptase adjacent to the 
catalytic site and it leads to conformational changes and inactivates the RNA‐dependent and 
DNA‐dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic 
site. Resistance develops rapidly in cells exposed to Nevirapine. High resistance is associated 
with mutations at reverse transcriptase codons 101,103,106.108,135,181,188 and 190. 
 
 
 
 
Pharmacokinetics  
Absorption: 
Nevirapine is absorbed rapidly after oral doses and absorption is not affected by food. 
Peak plasma concentrations occurs 4 hours after a single dose. Oral bio availability is greater 
than 90% 
Distribution: 
Nevirapine crosses the blood-brain barrier with a ratio of cerebrospinal fluid to serum 
concentrations of about 0.45. Binding to plasma protein is reported to be up to 36%. 
Nevirapine crosses the placenta and is distributed into breast milk. Nevirapine is about 60% 
bound to plasma proteins. 
Metabolism: 
Nevirapine extensively metabolized by hepatic microsomal enzymes, principally by 
cytochrome P450 iso enzymes of CYP3A family and produces several metabolites including 
2-, 3-, 8-, and 12- hydroxy nevirapine. Auto induction of these enzymes results in a 1.5 to 2 
fold increase in apparent clearance after 2 to 4 weeks of administration of usual doses, and 
decrease in terminal half life from 45 hours to 25-30 hours over the same period. 
Elimination:  
Nevirapine is mainly excreted in urine as glucuronide conjugates of the hydroxylated 
metabolites. 
Bioavailability: 90% 
Half-life elimination: 25 to 30 hours 
Excretion: Urine 
Drug interactions 
 
 
Nevirapine induces CYP3A4 enzyme, co administration with agents metabolized by 
this system may lower the plasma levels. Methadone withdrawal has been reported in patients 
receiving Nevirapine. Rifampicin and ketoconazole are contraindicated in patients receiving 
nevirapine. Plasma ethylestradiol levels decrease significantly with nevirapine 
coadministration. Although Nevirapine can lower plasma concentrations of protease 
inhibitors, most such combinations do not require dose adjustment. 
Adverse reactions  
The most common adverse effect of Nevirapine is skin rash, usually occurring within 
first 6 weeks of starting therapy. Severe and life-threatening skin reactions have occurred, 
including stevens-johnson syndrome, and rarely, toxic epidermal necrolysis. Hypersensitivity 
reactions including angioedema, utricaria, and anaphylaxis have been reported. Severe 
hepatotoxicity, including hepatitis and hepatic necrosis, occasionally fatal, has occurred and 
may be more prevalent in women and patients with high CD4 cell counts at the start of 
treatment. Other common adverse effects include nausea, vomiting, diarrhea, abdominal pain, 
fatigue, drowsiness and head ache. 
 Clinical uses 
 Nevirapine is FDA-approved drug for treating HIV infection in adults and children, 
in combination with other antiretroviral agents. It can be very effective during long-term 
administration in multi drug regimens. 
Dosage and administration: 
HIVinfection 
Adult: 200mg once daily for first 14 days, then increased to 200mg twice daily provided that 
no rash is present 
Child: 2months- 8 years: 4mg/kg once daily for 14 days and then if no rash is present, 
7mg/kg twice daily. 
8 to 16 years: 4mg/kg once daily for 14 days and then 4mg/kg twice daily thereafter. 
 
 
 
 4.2 POLYMER PROFILE 
Human serum albumin53,54,55,56,57 
Synonym: human serum albumin; HSA  
Structure: 
           The molecular weight of HSA has frequently been cited as 66,120 or 66,267, but it 
was revised in 1990to 66,430. All three values are based on amino acid sequence 
information. HSA is a single polypeptide chain consisting of about 583 amino acid residues 
and no carbohydrates. At pH 5-7 it contains 17 intra chain disulfide bridges and 1 sulfahydryl 
group. 
Physicl properties:  
Appearance   : powder –white to light tan 
Solutions   : clear to slightly hazy and amber 
PI in water at 250 c  : endogenous material 
Fatty Acid Depleted  : 5.3 
pH of 1% Solution  : 5.2-7 
Intrinsic viscosity,   : 0.0413 
Stability/ storage  : if stored at 2-80 c, HSA powders and HSA solutions were 
stable         
for a minimum of 2.5 years 
Solubility/ solution stability: 
          Albumins are readily soluble in water and can only be precipitated by high 
concentrations of neutral salts such as ammonium sulfate. The solubility of powdered HSA in 
deionised water at 40 mg/ml and obtains clear to very slightly hazy, faint yellow solutions. 
The solution stability of HAS is very good (especially if the solutions are stored as frozen 
laliquots). However albumin is readily coagulated by heat. When heated to 500c or above, 
albumin quite rapidly forms hydrophobic aggregates, which do not revert to monomers upon 
 
 
cooling. At somewhat lower temperatures aggregation is also expected to occur, but at 
relatively slower rates. 
   
Product description / usage: 
         Albumins are a group of acidic proteins, which occur plentifully in the body fluids, and 
tissues of mammals and in some plant seeds. Unlike globulins, albumins have comparatively 
low molecular weights, are soluble in water, are easily crystallized, and contain an excess of 
acidic amino acids. Serum and plasma albumin is carbohydrate- free and comprises 55-62% 
of the protein present. 
   Albumin binds water, Ca2+ ,Na+  and K+  due to a hydrophobic cleft, albumin binds fatty 
acids, bilirubin, hormones and drugs. The main biological function of albumin is to regulate 
the colloidal osmotic pressure of blood. Human and bovine albumins contains 16%nitrogen 
and are often used as standards in protein calibration studies. Albumin is used solubilise 
liquids, and is also used as a blocking agent in westeron blots or ELISA applications. 
Globulin free albumins are suitable for  use  in applications where no other proteins should 
present (e.g.,electrophoresis). 
Applications : 
• Antibody purification 
• Binding and transport studies 
• Blood banking reagents 
• Culture media (microbial) 
• Cell culture (general) 
• Electrophoresis(M.W.standard) 
• ELISA (blocking reagent) 
• ELISA (non specific binding) 
• Enzyme systems 
• Hapten carrier  
• Immunocytochemistry 
• Immunohematology  
• Mitogenic assays 
 
 
• Molecular biology 
• Protein base or filler 
• Protein supplement  (controls)  
• Protein standard (M.W.,amino acids) 
• RIA systems 
• seriology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.0 AIM AND SCOPE OF THE STUDY 
            Nevirapine (NVP), a non-nucleoside reverse transcriptase inhibitor, is one of the most 
prescribed antiretroviral drugs for reducing the morbidity and mortality related to the 
infection of human immunodeficiency virus (HIV). NVP has been widely applied as a 
prophylaxis dose against mother-to-child HIV transmission in developing countries .In 
combination therapy, NVP was used in the initial regimen to reduce impacts on the clinical 
implications of drug resistance. Nevirapine is currently available in two dosage forms namely 
tablets and suspensions. commercially nevirapine is highly hydrophobic and very poorly water 
soluble. Nevirapine is a BCS class II  drug and therefore  poses a challenge in the design of dosage 
form due to its low aqueous solubility. Besides its poor solubility  may also aspects the bioavailability 
of the drug. 
 
 
Albumin is an attractive macromolecular carrier and widely used to prepare 
nanospheres and nanocapsules, due to its availability in pure form and its biodegradability, 
nontoxicity and non immmunogenicity. Both Bovine Serum Albumin or BSA and Human 
Serum Albumin or HSA have been used. As a major plasma protein, albumin has a distinct 
edge over other materials for nanoparticle preparation. On the other hand, albumin 
nanoparticles are biodegradable, easy to prepare in defined sizes, and carry reactive groups 
(thiol, amino, and carboxylic groups) on their surfaces that can be used for ligand binding 
and/or other surface modifications and Based on albumin nanoparticles offer the advantage 
that ligands can easily be attached by covalent linkage. Drugs entrapped in albumin 
nanoparticles can be digested by proteases and drug loading can be quantified.  
 
 
   Based on the above considerations the present study proposed to develop nevirapine 
nanoparticles using human serum albumin with different polymer ratios and to evaluate the 
nanoparticles for physico-chemical, in-vitro, in-vivo release characterstics. The findings of 
the polymer may help design a better and controlled release system with improved 
bioavailability of nevirapine. 
 
 
 
 
 
The following parameters were examined 
1. Pre-formulation studies. 
a) Drug and carrier interaction by FT-IR spectroscopy. 
b) Drug and carrier interaction by Differential Scanning  Calorimetry(DSC) 
2. Preparation of standard curve of Nevirapine in pH 1.2 and 7.4 Phosphate Buffer 
3. Preparation of Nevirapine loaded albumin nanoparticles by Desolvation method. 
4. Evaluation of Nevirapine loaded albumin nanoparticles 
a) Drug and carrier interaction by FT-IR spectroscopy. 
b) Particle size determination  by Scanning Electron Microscopy(SEM) 
c) Surface characteristic by Zeta potential analyzer 
d) Thermal analysis by Differential Scanning Calorimetry (DSC). 
e) Nevirapine encapsulation efficiency and percentage yield of the nanoparticles. 
f) Invitro release of nevirapine from the nanoparticles. 
Dissolution studies 
Diffusion studies 
Based on the conditions  of  in vitro release best sample was used for in vivo studies 
in animal model. 
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                      7.0  MATERIALS 
Drugs and Chemicals 
Drugs and Chemicals - Supplier/ Manufacturer 
Nevirapine       - Ranbaxy labs Pvt. Ltd .Mumbai. 
Human serum albumin    - (Sisco Research Lab. Bombay) 
25%glutaraldehyde     - (Loba Chemie Bombay) 
HPLC water      -  Merck Pvt, Ltd Mumbai. 
99% Absolute Alcohol 
(Changshu Yangyuan Chemical, China), 
 
Sodium Hydroxide     - Spectrum Reagents & Chemicals, Cochin 
Potassium Dihydrogen Phosphate   - Spectrum Reagents & Chemicals, Cochin 
Sodium Tri Poly Phosphate    - S.D Fine chem. Ltd, Mumbai 
Dialysis membrane 110    - Himedia Laboratory, Mumbai 
Programmable Dissolution Apparatus -Veego (Mumbai) 
 
 
 
 
 
 
 
7.1 INSTRUMENTS 
Instruments - Model/ Manufacturer 
FT-IR spectrophotometer    - Perkin Elmer Spectrum RX 1 
Scanning electron microscope   - Joel model JSM 6400, Tokyo 
UV-Visible Spectrophotometer   - Perkin Elmer Lambda 25 
Single pan digital balance   - Shimadzu BL220H 
Microscope - Unilab 
Digital pH meter     - Hanna instruments, Italy HI98 
Magnetic stirrer     - Eltek MS 2012. 
Sonicater - Bandelin Sono plus Model HD , 2070 
Freeze Drier      - Labconico, USA 
Research centrifuge - Hitachi Centrifuge USA 
Differential Scanning Calorimetry   - DSC DA 60 Shimadzu.Japan 
Zeta potential analyzer    - Zetasizer 3000HS,Malvern instrument, UK. 
 
 
 
 
 
 
 
 
 
8.0  METHODS 
 
8.1 PREFORMULATION STUDIES 58,59 
Before formulation of drug substances into a dosage form, it is essential that the drug 
and polymer should be chemically and physically characterized. Preformulation studies give 
the information needed to define the nature of the drug substance and provide a framework 
for the drug combination with pharmaceutical excipients in the fabrication of a dosage form. 
Fourier Transform Infra Red Spectroscopy (FTIR) 
Compatibility study of drug with the polymer was determined by FTIR Spectroscopy 
using Perkin Elmer RX1. The pellets were prepared by gently mixing of 1mg sample with 
200mg potassium bromide at high compaction pressure. The scanning range was 450 to 4000 
cm -1 and the revolution was 4 cm -1. The pellets thus prepared were examined and the spectra 
of drug and the polymer in the formulations were compared with that of pure drug or polymer 
spectra. 
Differential Scanning Calorimetry (DSC) 
Differential scanning calorimetric curve of pure nevirapine, human serum albumin 
(HSA) polymer and mixture of drug and polymer measurement were carried out by using a 
thermal analysis instrument equipped with a liquid nitrogen sub ambient accessory. 2-6mg 
samples were accurately weighed in aluminum pans thematically sealed and heated at a rate 
of 10ºC per min -1 in a 30 to 300 ºC temperature under nitrogen flow of 40 ml / min. 
8.2 Construction of standard curve for Nevirapine 60 
          Nevirapine can be estimated spectrophotometrically at 283nm as it obeys Beer's-
Lambert's law limit in the range of 2-20 µg/ml. 
Preparation of reagents 
Preparation of 0.1 N HCl 
           8.5 ml of concentrated HCl was dissolved in 1000 ml of distilled water. 
 
 
 
 
Stock solution 
          100 mg of Nevirapine was dissolved in 100 ml of 0.1 N HCl, to get a solution of 1000 
µg/ml concentration. 
Standard solution 
          10 ml of stock solution was made to 100 ml with 0.1 N HCl thus giving a concentration 
of 100 µg/ml. Aliquot of standard drug solution ranging from 0.5 ml, 1 ml, 1.5 ml, 2 ml and 
2.5 ml were transferred into 10 ml volumetric flask and were diluted up to the mark with 0.1 
N HCl. Thus the final concentration ranges from 2 – 20 μg. Absorbance of each solution was 
measured at 283 nm against 0.1 N HCl as a blank. A plot of concentrations of drug Vs 
absorbance was plotted. 
Preparation of Phosphate buffer pH 7.4  
50 ml of potassium Dihydrogen phosphate was placed in a 200ml volumetric flask and added 
39.1 ml of 0.2m sodium hydroxide and then distilled water to make up to 200ml. 
 
Preparation of 0.2m potassium Dihydrogen phosphate 
27.218g of potassium Dihydrogen phosphate was dissolved in distilled water and made up to 
1000 ml. 
 
Preparation of 0.2m sodium hydroxide 
8g of sodium hydroxide was dissolved in distilled water and made up to 1000 ml. 
Preparation of standard drug solution 
Stock Solution 
100mg of Nevirapine was dissolved in 100ml of Phosphate buffer saline pH 7.4 so as to get a 
stock solution of 1000 μg/ml concentration. 
 
 
 
 
 
 
 
Standard Solution 
2 ml of stock solution was diluted to 100ml with pH 7.4 phosphate buffer thus giving 
a concentration of 20 μg/ml of the drug .Aliquot of standard drug solution ranging from 1ml 
to 9ml were transferred 10ml volumetric flask and were diluted up to the mark with pH 7.4 
phosphate buffer. Thus the final concentration ranges from 2-20 μg/ml as per Beer Lambert’s 
law. Absorbance of each solution was measured at 283.0 nm against phosphate buffer pH 7.4 
as a blank and the concentration of drug Vs absorbance was plotted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Standard curve of Nevirapine 
The standard curve of Nevirapine was determined in 0.1 N HCL (pH 1.2) by using 
UV-Visible spectrophotometer at 283 nm. Graph was plotted by taking absorbance (nm) on 
X-axis verses concentration (µg/ml) on Y-axis and it is follows the Beer's law. The results 
were shown in table 4. 
                     Standard curve of Nevirapine in 0.1 N Hcl 
Concentration (µg/ml)  Absorbance (at 283nm) 
0  0
2  0.113
4  0.234
6  0.382
8  0.516
                        10  0.652
12  0.723
Slope  0.026
R2  0.998
      
   Table 4 standard curve of nevirapine pH 1.2 
 
Fig 2 standard curve of nevirapine pH 1.2 
 
 
 
 
Preparation of standard graph of Nevirapine in pH 7.4 phosphate buffer 
Standard graph for the drug nevirapine was done in pH 7.4 phosphate 
buffer.Table 5  shows the concentrations of nevirapine in pH 7.4 phosphate buffer and 
the respective absorbances. I t  shows the standard graph of nevirapine in 7.4 phosphate 
buffer. 
Spectrophotometric data for standard curve of Nevirapine in pH 7.4 phosphate 
buffer       
Concentration (µg/ml)  Absorbance (at 283nm) 
0  0
2  0.089
4  0.187
6  0.286
8  0.369
                        10  0.458
12  0.540
Slope  0.045
R2  0.999
      Table 5 standard curve of nevirapine pH 7.4 
  
                           
Fig 3 standard curve of nevirapine pH 7.4 
 
 
 
8.3 PREPARATION OF NEVIRAPINE LOADED HUMAN SERUM ALBUMIN 
(HSA) NANOPARTICLES61 
 
       The formula of nevirapine nanoparticles is given in table no-6 . Nevirapine 
nanoparticles were prepared by desolvation technique. Human serum albumin (HSA) 
nanoparticles were prepared by a desolvation technique as described previously (Marty et al 
1978). In this method 200mg of drug was dissolved in 100ml of ethanol. The drug containing 
ethanol solution was dropwise introduced into the different concentrations of human serum 
albumin solution (200mg,400mg,800mg).To the above mixture 25%glutaraldehyde solution 
was added and the mixture was continuously stirred for   2 hrs followed by sonication for 
5mins. The obtained nanoparticles were seperated by cold centrifuged at 12000rpm in a 
glucose bed for 30mins using Hitachi centrifuge. The supernetantent liquid was analysed by 
spectrophotometer to caliculate the percentage drug entrapment and drug loading. The final 
suspension was then frozen and lyophilized at 0.4 mbar and -40oC for 5 hrs using glucose and 
lactose (1:2) as cryoprotective agents. The lyophilised nanoparticles were stored in a 
desicator at 40C. 
 
 
Table 6    Nevirapine loaded HSA nanoparticles 
 
Formulation   
code 
Drug Polymer Drug  polymer 
ratio 
Sonication 
time 
F1 200mg 200mg 1:1 5mins 
F2 200mg 400mg 1:2 5mins 
F3 200mg 800mg 1:4 5mins 
 
 
 
 
8.4 EVALUATION OF NANOPARTICLES 
8.4.1 Drug and carrier interaction by Fourier Transform Infra Red Spectroscopy 
          Compatibility study of drug with the polymer was determined by FTIR Spectroscopy 
using Perkin Elmer RX1. The pellets were prepared by gently mixing of 1mg sample with 
200mg potassium bromide at high compaction pressure. The scanning range was 450 to 4000 
cm-1 and the revolution was 4 cm-1.  
 8.4.2 Particle size determination by Scanning Electron Microscopy 62 
       The size of the nanoparticles was analyzed by scanning electron microscope .The 
instrument used for this determination was JEOL MODEL JSM 6400 scanning electron 
microscope (SEM). The nanoparticles were mounted directly on the SEM stub, using double 
–sided, sticking tape and coated with platinum and scanned in a high vacuum chamber with a 
focused electron beam. Secondary electrons, emitted from the samples were detected and the 
image formed. 
 
 Surface Characteristics by Zeta Potential 
             The Zeta potential of nanoparticles was measured on a zeta potential analyzer 
Zetasizer 3000 HS Malvern instrument. The samples were diluted with  pH 7.4 and placed in 
eletrophoretic cell and measured in the automatic mode. 
8.4.3 Thermal Analysis by Differential Scanning Calorimetry (DSC) 
                   Differential scanning calorimetric measurement of nevirapine, human serum 
albumin nanoparticles  was carried out by using a thermal analysis instrument equipped with 
a liquid nitrogen sub ambient accessory. 2-6mg samples were accurately weighed in 
aluminum pans thermatically sealed and heated at a rate of 10ºC per min -1 in a 30 to 300ºC 
temperature under nitrogen flow of 40 ml / min. 
8.4.4 Encapsulation efficiency and Percentage yield of the nanoparticles 63 
      
 The Encapsulation efficiency and percentage yield of the nanoparticles were 
determined by the separation of nanoparticles from the aqueous medium containing non 
associated nevirapine by cold centrifugation at 12000g for 30 minutes.The amount of free 
nevirapine in the supernatant was measured by UV method at 283 nm. The nevirapine 
encapsulation efficiency (EE) and  percentage yield of the nanoparticles was calculated as 
follows. 
 
 
 
 
                                             Total amount of Nevirapine – Free Nevirapine 
Encapsulation efficiency = -------------------------------------------------------- x 100 
                                                              Weight of nanoparticles 
                                  Total amount of Nevirapine – Free Nevirapine 
Percentage yield = --------------------------------------------------------- × 100 
                                               Total amount of Nevirapine 
 
8.4.5  Invitro release of nevirapine from the nanoparticles 
Dissolution studies 
The dissolution profiles of the plain drug and the nanoparticle formulations were 
determined in USP dissolution apparatus – II using 900ml of pH – 1.2 buffer for the first 2 
hrs and continued with Phosphate buffer pH – 7.4. The dissolution media were maintained at 
37°±0.5°C with a paddle rotation speed at 50 rpm. The amount of drug used was equivalent 
to 2 mg. At specified time intervals (0.5,1,2,4,6,8,10,12,and24hrs) 5ml of dissolution media 
were withdrawn and replaced with an equal volume of the fresh medium to maintain constant 
volume of the media. Samples were filtered through a 0.22μm nylon membrane filter 
(Millipore, Bedford, MA) and assayed for drug content spectrophotometrically at 283nm 
using UV/Vis double beam spectrophotometer after appropriate dilution with the 
corresponding media. Cumulative percentage of drug dissolved in the preparations was 
calculated using calibration equations. Dissolution tests were performed in triplicate for each 
formulation (n = 3).64 
 
8.4.6 Diffusion studies 
The nevirapine loaded human serum albumin (HSA) nanoparticles were separated 
from the aqueous suspension medium through ultracentrifugation. Nanoparticles equivalent 
to 2mg of nevirapine nanoparticles were redispersed in 10ml  phosphate buffer solution pH-
7.4 and placed in a dialysis membrane bag with a molecular cut-off of 5 kDa which acts as a 
donor compartment, tied and placed into 10 ml 7.4 phosphate buffer solution in a beaker 
which acts as a receptor compartment .The entire system was kept at 37ºC with continuous 
magnetic stirring. At appropriate time intervals (1, 2, 3, 4,6,8,10,12,14,16,18,20,22 and 24 
hrs), 1 ml of the release medium was removed and 1 ml fresh 7.4 phosphate buffer solution 
 
 
was added in to the system. The amount of nevirapine in the release medium was evaluated 
by UV-Visible Spectrophotometer at 283 nm. 
 8.4.7 Kinetics of drug release65,66 
In order to understand the mechanism and kinetic of drug release, the drug release 
data of the in-vitro dissolution study were analyzed with various kinetic models like zero 
order, first order, Higuchi’s, Peppa’s and Coefficient of correlation (r) values were calculated 
for the linear curves by regression analysis of the above plots. 
I) Fitting of Results into Different Kinetic Equations 
The results of in vitro release profile obtained for all the formulations were plotted in 
modes of data treatment as follows: -  
1. Zero - order kinetic model - Cumulative % drug released versus time. 
2. First – order kinetic model - Log cumulative percent drug remaining versus 
time. 
3.  Higuchi’s model - Cumulative percent drug released versus square root of 
time. 
4. Korsmeyer equation / Peppa’s model - Log cumulative percent drug released 
versus log time. 
A) Zero order kinetics  
Zero order release would be predicted by the following equation 
At = A0 – K0t    
Where,  
At   = Drug release at time‘t’. 
A0  = Initial drug concentration. 
K0  = Zero - order rate constant (hr-1). 
 
 
When the data plotted as cumulative percent drug release versus time, and the plot is 
linear, and then the data obeys Zero – order equal to K0. 
 
B) First Order Kinetics 
First – order release would be predicted by the following equation:- 
Log C = log C0 – Kt / 2.303 
Where,      C   = Amount of drug remained at time‘t’. 
      C0 = Initial amount of drug. 
      K   = First – order rate constant (hr-1). 
When the data plotted as log cumulative percent drug remaining versus time yields a 
straight line, then the release follow first order kinetics. The constant ‘K’ can be obtained by 
multiplying 2.303 with the slope values.  
C) Higuchi’s model 
Drug release from the matrix devices by diffusion has been described by following 
Higuchi’s classical diffusion equation 
Q = [Dε / τ (2 A - εCs) Cst] ½ 
Where, 
Q = Amount of drug released at time‘t’. 
D = Diffusion coefficient of the drug in the matrix. 
A = Total amount of drug in unit volume of matrix. 
Cs = the solubility of the drug in the matrix. 
ε = Porosity of the matrix. 
τ = Tortuosity. 
 
 
t = Time (hrs) at which ‘q’ amount of drug is released. 
Above equation may be simplified if one assumes that ‘D’, ‘Cs’ and ‘A’ are constant. 
Then equation becomes            
Q = Kt1/2 
When the data plotted according to equation i.e. cumulative drug release versus 
square root of time yields a straight line, indicating that the drug was released by diffusion 
mechanism. The slope is equal to ‘K’ (Higuchi’s 1963). 
D) Korsmeyer equation / Peppa’s model  
To study the mechanism of drug release from the sustained-release of acyclovir 
nanoparticles, the release data were also fitted to the well-known exponential equation 
(Korsmeyer equation/ peppa’s law equation), which is often used to describe the drug release 
behavior from polymeric systems. 
Mt / Mα = Ktn 
Where, Mt / Mα = the fraction of drug released at time‘t’.  
             K = Constant incorporating the structural and geometrical characteristics of the drug / 
polymer system. 
              n = Diffusion exponent related to the mechanism of the release. 
Above equation can be simplified by applying log on both sides, 
And we get: - Log Mt / Mα = Log K + n Log t 
When the data plotted as log of drug released versus log time, yields a straight line 
with a slope equal to ‘n’ and the ‘K’ can be obtained from y – intercept. For Fickian release 
‘n’ = 0.5 while for anomalous (non - Fickian) transport ‘n’ ranges between 0.5 and 1.0. 
 
 
 
 
Table 7 : Mechanism of Drug Release as per Korsmeyer Equation / Peppa’s 
Model 
S. No. n Value Drug release 
1.  0.50 Fickian release 
2.  0.5 < n <1.0  Non – Fickian release 
3.  1.0 Class II transport 
E). Statistical analysis 
The release data were subjected to ANOVA with Tukey-Kramer multiple comparision 
test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.5  In-vivo Evaluation studies: 
Animals: New Zealand white rabbits weighing 1.5 to 2.5kg were obtained from 
Swamy Vivekananda College of pharmacy animal house and used in this study. The animals 
were fed with cabbage and water. They were maintained in standard laboratory conditions at 
21±2 0C and relative humidity of 55-60%. The animals were fasted overnight before the 
experiment. The study protocol was approved by the Institutional Animal Ethical Committee 
and the protocol number is SVCP/IAEC/M.Pharm/08/2013. 
 
Requirements:  Cotton 
     Surgical blade 
     26G needle 
     Blood collecting tubes (EDTA tubes)         
     Plasma sample collecting tubes 
 
Sex: Male 
 
No. of animals: 06 
 
Animal dose:  
 
Nevirapine: 20mg/kg 
Nevirapine nanoparticles:12.5mg/kg 
 
Procedure for collection of blood: 
  
Collection of blood from marginal ear vein: 
 
 The animal was placed in a restainer. Hair of the ear was shaved smoothly with blade 
without disturbing the blood vessels. Ear was cleaned with 95% v/v alcohol on the collection 
site and rapid rubbing on the ear to  dilate blood vessels which is easy to collect the blood. 2G 
needle was inserted in vein to collect the blood from marginal ear vein. After collecting 
blood, clean sterile cotton was kept on the collection site and finger pressure was applied to 
stop the bleeding.69 
 
 
 
Experimental procedure: Rabbits were classified into 2 different groups each group 
consisting of 6 animals 
 
GROUP I Nevirapine 
GROUP II Nevirapine nanoparticals 
 
Procedure : After overnight fasting, Group1, and Group 2, animals received 
Niverapine (20mg/kg), Niverapine nanoparticals (12.5mg/kg) respectively through an 
intragastric tube. Blood samples (1 ml) were collected in heparinized tubes from the marginal 
ear vein at 0, 0.5, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12 and 24 h after drug administration and 
plasma was separated by using centrifugation and stored at -20°C. Samples were analysed by 
validated high performance liquid chromatography (HPLC).68 
 
Bioanalytical work: 
 
Extraction of nevirapine and nevirapine nanoparticle from plasma: 
An aliquot of 500µl of plasma samples was pipetted into an eppendrof’s tube of 1.5ml 
capacity. 500µl ethyl acetate was added, vortexed for 3 minute and centrifuged at 10,000 rpm 
for 15min. Then 300 µl of the supernatant was taken into another microcentrifuge tube and 
vaccum dried in centrivac. The residue obtained was reconstituted in 100µl of mobile phase. 
Plasma was filtered through 0.22 µm membrane (13 mm) and 20 µl volumes was injected. 
All the two analytes; NVP and NVP NP were detected at 283nm70 
Hplc analysis: 
Preparation of mobile phase: 
  Potassium dihydrogen phosphate buffer was weighed (131.6g) and dissolved in 1000ml of 
water to get 1M solution. From this solution 15ml was taken and volume was made up to 
100ml to get a solution of 15mM. The pH of the solution was adjusted to 3.2 with ortho 
phosphoric acid. The final volume was adjusted with acetonitrile, which resulted in pH 3.5 
for final mobile phase. The final solution was mixed well and sonicated for 10 min and 
filtered using whatman filter paper. 
 
 
 
 
Chromatographic condition: 
A water reverse phase C-18 column, equilibrated with mobile phase 15mM aqueous 
phosphate buffer: acetonitrile was used. The active principle was eluted isocratically and the 
mobile phase flow rate maintained at 1.0 mi/min. the effluents were mentioned at 283 nm 
with the detector. The sample was injected using a 20µl fixed loop, and the total run time was 
10min. 
 
Extraction efficiency: 
 
 The extraction efficiency was calculated by comparing the peak heights of nevirapine 
spiked-pooled blank plasma samples with that of respective standard nevirapine samples 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.5.1 Pharmacokinetic parameters71 
 
 The pharmacokinetic parameters were calculated for each rabbit of group I, group II, 
by the semi logarithmic plot of plasma nevirapine concentration at various intervals. The 
following pharmacokinetic parameters were calculated: 
 
1. Elimination rate constant (Ke): The elimination rate constant was determined using 
the formula 
Ke = -2.303 x slope of extrapolated curve 
 
2. Elimination half life (t1/2): t1/2 was calculated using the formula 
 
t1/2 = 0.693/Ke 
 
3. Absorption rate constant (Ka): This was determined by the method of residuals. The 
log linear portion of the decline phase was back extrapolated for each curve. The 
plasma concentration along this extrapolated line was C. the observed plasma 
concentration C was subtracted from the corresponding extrapolated value at each 
time point. The semi logarithmic plot of residuals (C-C) against time yields a straight 
line. 
 
Ka = -2.303 x slope of residual line 
4. Absorption half life: It was calculated using the formula 
 
T1/2(a) = 0.693/Ka 
 
5. Apparent volume of distribution (Vd): It was calculated using the formula 
 
Vd =             Ka F X0 
   (Ka - Ke) y intercept 
 
6. Time to Cmax (tmax): tmax was calculated using the formula 
tmax =        ln Ka - ln Ke 
             Ka-Ke 
 
 
7. Maximum plasma concentration (Cmax): Cmax was calculated using the formula 
 
Cmax =    Y intercept (e-Ke. Tmax – e-Ka. Tmax) 
 
 
8. Area under curve (AUC0-12): AUC0-12 was calculated using the formula 
 
 
AUC   =       F X0 
                Vd.Ke 
 
9. AUC0-∞ was calculated using the formula 
 
 
AUC0-∞ =     C0 
             Ke 
 
 
STATISTICS: 
The values are expressed in mean ± SEM. One way ANOVA followed by Tukey’s 
multiple comparison Test was used to analyse the effect of different doses of silymarin when 
compared to control, with the help of Graph Pad Instat software, version 3.01. P<0.05 
considered as significant.                 
 
 
 
 
 
 
 
 
 
 
 
    9.0 RESULTS 
 
9.1 COMPATIBILITY STUDIES 
A. Drug and carrier intereaction by FT-IR Spectroscopy  
FT-IR spectra of nevirapine, human serum albumin in physical mixture of nevirapine 
and HSA and nevirapine loaded albumin nanoparticles are shown in tables8,9,10 and 11 and 
figures 4,5,6 and 7. Nevirapine showed from characterstic peaks at 2885.6 cm-1 (C-H-alkyl 
strecting),1699.34 cm-1(C=O-aromatic ketones), 1651.34cm-1(COOH unsaturated carboxylic 
acid stretching),3043.77cm-1(O-H carboxylic acid-stretching). All these characteristic peaks 
of nevirapine  were present in the spectra of either physical mixture  or nanoparticles  thus 
confirming compatability of the drug with polymer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sl.no 
 
 
IR Spectrum 
 
 
Peaks(cm-1) 
 
Groups 
 
Stretching 
/Deformation 
 
 
 
 
1 
 
 
 
 
Nevirapine  
 
2885.6 C-H(alkyl) 
 
Stretching 
1699.34 C=O(aromatic ketone) Stretching 
 
1651.12 COOH(unsaturated carboxylic acid) 
 
Stretching 
3043.77 O-H(Carboxylic acid) Stretching 
 
Table 8 IR SPECTRUM OF NEVIRAPINE 
 
 
            Fig 4  IR SPECTRUM OF NEVIRAPINE 
                                      
 
 
 
 
 
 
 
 
 
 
2 
 
 
Blank 
nanoparticles of 
Human serum 
albumin 
2872.1 C-H(alkyl) Stretching 
1653.05 C=O(aromatic ketone) Stretching 
 
1629.6 COOH(unsaturated carboxylic acid) 
 
Stretching 
3084.28 O-H(Carboxylic acid) Stretching 
 
 
Table 9 IR SPECTRUM OF BLANK NANOPARTICLES USING HSA 
 
Fig 5    IR SPECTRUM OF BLANK NANOPARTICLES USING HSA 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Physical mixture 
of Nevirapine 
and  Human 
serum albumin 
2891.39 C-H(alkyl) Stretching 
1697.41 C=O(aromatic ketone) Stretching 
 
1651.12 COOH(unsaturated carboxylic acid) 
 
Stretching 
3045.7 O-H(Carboxylic acid) Stretching 
 
Table 10 IR SPECTRUM OF PHYSICAL MIXTURE OF NEVIRAPINE WITH HSA 
 
 
  Fig 6 IR SPECTRUM OF PHYSICAL MIXTURE OF NEVIRAPINE WITH HSA 
 
 
 
 
 
 
 
 
 
 
4 
 
 
Nevirapine  
nanoparticles of 
Human serum 
albumin 
2856.67 C-H(alkyl) Stretching 
1654.98 C=O(aromatic ketone) Stretching 
 
1645.03 COOH(unsaturated carboxylic acid) 
 
Stretching 
2926.11 O-H(Carboxylic acid) Stretching 
 
Table 11   IR SPECTRUM OF NEVIRAPINE NANOPARTICLES 
 
 
                           Fig 7 IR SPECTRUM OF NEVIRAPINE NANOPARTICLES 
 
 
 
 
 
 
 
B. Differential scanning calorimetry (DSC) 
 
In order to confirm the physical state of Nevirapine in the nanoparticles, DSC of 
the NVP, physical mixture of NVP and polymer, NVP nanoparticles and blank 
nanoparticles,was carried out and the results are shown in figures 8,9,10,11,12 and 13. The 
DSC thermogram of of NVP showed a sharp endothermic peak at 94.96°C, its melting 
point. The physical mixture of NVP and polymer, showed  the  same  thermal  behavior  
93.04°C  as  the individual component, indicating that there was no interaction between the 
NVP and the polymer in the solid state. The DSC thermogram of blank nanoparticles 
showed a single endothermic peak at 80.72°C, the melting point of HSA. The 
nanoparticles of F1,F2 and F3, showed endothermic peak at 68.75°C, 81.59°C and 
92.05°C  respectively,which are the characterstic peaks of  HSA shifted from 80.72°C , 
and there was no evidence for presence of the character peaks of  NVP at 94.96°C in 
F1,F2 and F3. The change in thermogram indicate that NVP existed in an amorphrous form 
completely where as the HSA partially changes to amorphous state.  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Fig 8   DSC thermogram of nevirapine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             Fig 9 DSC thermogram of blank nanoparticles using Human serum albumin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig 10 DSC thermogram of  physical mixture of nevirapine and human serum albumin 
 
 
 
 
 
 
 
 
 
 
 
           Fig 11  DSC thermogram of Nevirapine nanoparticles using Human serum 
albumin  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           Fig 12   DSC thermogram of Nevirapine nanoparticles using Human serum 
albumin  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 13   DSC thermogram of Nevirapine nanoparticles using Human serum 
albumin 
 
 
 
 
 
 
 
 
 
 
 
9.2 Encapsulation efficiency and  percentage yield: 
The entrapment efficiency of F1,F2 and F3 were 58.54%, 68.44% and 73.12% 
respectively. Similarly the percentage yield increses in the concentration of HSA increases. 
The percentage yield of F1,F2 and F3  were 50.91,60.46 and 83.86 respectively. Table 12 
shows the results of encapsulation efficiency and percentage yield of the nevirapine 
nanoparticles. 
Formulation 
Code 
Drug polymer 
ratio (mg) 
Encapsulation 
efficiency (%) 
Percentage yield 
(%) 
F1 1:1 58.54 50.91 
F2 1:2 68.44 66.46 
F3 1:4 73.12 83.86 
 
Table 12 encapsulation efficiency and percentage yield of the   
nanoparticles 
Morphology: 
           The SEM of nanoparticles are shown in figures, The particles was formed disperse and 
irregular in shape at the drug:polymer ratio 1:1 in F1 and remained  in the same characterstic  
at higher concentration of the polymer as seen in F2 and F3 formulations.  
SEM IMAGES: 
Fig 14  (F1) 
 
 
 
 
Fig 15 (F2) 
 
 
 
Fig 16  (F3) 
 
 
9.3 PARTICAL SIZE: 
The mean particle size of F1, F2 and F3 formulations , obtained by zetasizer analysis 
were  298,495 and 698nm (table 13) respectively. The particle size of nanoparticles was 
found increases with increase in the polymer concentration. 
 
 
Table 13 Particle size, Zeta potential and PDI of nevirapine loaded  nanoparticles 
Formulation 
code 
Drug  
polymer 
ratio (mg) 
Particle size Zeta 
potential(mv)
PDI 
F1 1:1 298±0.25nm -0.27±1.2mV 0.195±0.35 
F2 1:2 495±0.12nm -0.22±2.8mV 0.238±0.39 
F3 1:4 698±0.52nm -0.18±1.8mV 0.435±0.51 
  
9.3.1 Zeta potential: 
         The zeta performed of F1, F2  and F3 formulations are shown in table 13. The zeta 
potential of nanoparticles ranges from  -0.18 to -0.27 the least zeta potential with F3 and the 
ahighest value with F1. The zeta potential decreases with increase in the concentration of the 
polymer. 
9.3.2 Polymer dispersive index: 
      The PDI of F1,F2 and F3 are shown in table. The PDI  of all these formulations 
easily formed to be less than 0.5 indicating homogenous dispersion of the drug. The results 
are showed in table 13. 
 
Fig 17 Nevirapine zeta 
 
 
9.4   In vitro release of nevirapine nanoparticles 
The dissolution profile of F1,F2 and F3  are presented in tables 14,16 and 18. The 
present drug dissolved at every time point interval significantly dispersed between F1,F2 and 
F3. The dissolution rate with F2 and F3 was slower compared  to F1  
The t50 values of F1, F2 and F3 were also compared. The data are F1 Vs F2 (P<0.05); F1 Vs 
F3 (P<0.001); F2 Vs F3 (P<0.05). There was no significant difference in t50   value between 
F1 and F2, however significant differences observed between F1 and F3.     
 
Table 14     In vitro release data for nevirapine loaded nanoparticles     
formulation (F1) 
Time (hrs) 
       Cumulative Percent Drug Release 
Trial 1 Trial 2 Trial 3 Mean ± SD 
 0 0 0 0 0 
0.5 16.65 16.45 16.53 16.51±  0.62 
1 23.35 23.29 22.28 23.22±  0.49 
2 29.68 29.54 29.61 29.58±  0.69 
4 36.68 36.54 36.57 36.59±  0.68 
‘6 43.59 43.42 43.45 43.48±  0.67 
8 56.81 56.69 56.65 56.72.±  0.60 
10 63.65 63.45 63.49 63.52±  0.67 
12 70.59 70.39 70.45 70.48±  0.52 
24 91.29 91.45 91.25 91.36±  0.68 
                      
 
 
 
      Fig 18 Percentage Drug Release 
 
Table 15      Kinetic release data for nevirapine loaded nanoparticles(F1) 
Time in 
hrs 
Square 
root of 
time Log time 
 Cumulative 
%drug 
release 
Log 
cumulative 
%drug 
release 
Cumulative 
%drug 
remaining 
Log 
cumulative 
%drug 
remaining 
0 0 0 0 0 100 2
0.5 0.707 -0.301 16.51 1.217 83.49 1.921
1 1 0 23.22 1.365 98.63 1.994
2 1.414 0.301 29.58 1.47 98.53           1.993 
4 2 0.602 36.59 1.563 98.43 1.993
6 2.449 0.778 43.48 1.638 98.36 1.992
8 2.828 0.903 56.72 1.753 98.24 1.992
10 3.162 0.499 63.52 1.802 98.19 1.992
12 3.464 0.539 70.48 1.848 98.15 1.991
24 4.898 1.38 91.36 1.96 98.04 1.991
 
 
 
 
 
 
 
Table 16     In vitro release data for nevirapine loaded 
nanoparticles formulation (F2) 
Time (hrs) 
       Cumulative Percent Drug Release 
Trial 1 Trial 2 Trial 3 Mean ± SD 
 0 0 0 0 0 
0.5 15.52 15.39 15.35 15.45±  0.57 
1 21.65 21.35 21.52 21.47±  0.67 
2 27.62 27.53 27.49 27.56±  0.61 
4 33.75 33.59 33.52 33.66±  0.58 
6 40.51 40.39 40.35 40.42±  0.61 
8 46.65 46.56 46.49 46.53.±  0.59 
10 59.49 59.32 59.35 59.38±  0.47 
12 65.52 65.45 65.42 65.42±  0.55 
24 83.62 83.45 83.49 83.51±  0.52 
 
 
    Fig 18 Percentage of Drug Release 
 
 
Table  17  Kinetic release data for nevirapine loaded nanoparticles(F2) 
 
 
 
 
 
 
       
 
             
 
Fig 19 (a) 
Time 
in 
hrs 
Square 
root of 
time 
Log 
time 
 
Cumulative 
%drug 
release 
Log 
cumulative 
%drug 
release 
Cumulative 
%drug 
remaining 
Log 
cumulative 
%drug 
remaining 
0 0 0 0 0 100 2 
0.5 0.707 0.301 15.45 1.118 98.88 1.995 
1 1.414 0 21.47 1.331 98.66 1.994 
2 1.732 0.301 27.56 1.44 98.56 1.993 
4 2 0.602 33.66 1.527 98.47 1.993 
6 2.449 0.778 40.42 1.606 83.94 1.923 
8 2.828 0.903 46.53 1.667 98.33 1.992 
10 3.162 1 49.38 1.693 98.3 1.992 
12 3.464 1.079 65.48 1.816 98.18 1.992 
24 4.898 1.38 83.51 1.921 98.07 1.991 
 
 
F 
 
 
 
Fig 19 (b) 
 
Fig 19 (c) 
 
Fig 19 (d) 
 
 
 
 
Table 18  In vitro release data for nevirapine loaded nanoparticles formulation (F3) 
Time 
(hrs) 
Cumulative Percent Drug Release 
Trial 1 Trial 2 Trial 3 Mean ± SD 
0 0 0 0 0 
0.5 10.65 10.49 10.45 10.52±  0.64 
1 15.75 15.59 15.55 15.63±  0.57 
2 21.62 21.45 21.42 21.50±  0.60 
4 27.42 27.32 27.29 27.37±  0.62 
6 32.65 32.49 32.52 32.56±  0.59 
8 43.75 43.59 43.62 43.68.±  0.56 
10 54.75 54.65 54.69 54.62±  0.60 
12 60.61 60.52 60.45 60.49±  0.56 
24 71.68 71.51 71.46 71.55±  0.64 
       
 
         Fig 20 Percentage of Drug Release 
 
 
Table 19   Kinetic release data for nevirapine loaded nanoparticles(F3) 
Time sqrt log time 
% 
drug 
rel 
log % 
drug 
release 
% drug 
remaining
log % 
drug 
remaining 
0 0 0 0 0 100 2 
0.5 0.707 -0.301 10.65 1.027 98.97 1.995 
1 1 0 15.75 1.197 98.8 1.994 
2 1.414 0.301 21.62 1.334 98.66 1.994 
4 2 0.602 27.42 1.438 98.56             1.993 
6 2.449 0.778 32.65 1.513 98.56 1.993 
8 2.828 0.903 43.75 1.64 98.36 1.992 
10 3.162 0.499 54.75 1.738 98.26 1.992 
12 3.464 0.539 60.61 1.782 98.21 1.992 
24 4.898 1.38 71.68 1.855 98.14 1.991 
 
 
 
     
      
 
 
 
 
 
 
Fig 21 (a) 
 
 
 
 
 
Fig 21 (b) 
 
 
     Fig 21 (c) 
 
 
 
Fig 21 (d) 
 
 
Table 20 Comparative study for dissolution of nevirapine loaded nanoparticles 
Time (hrs) 
Cumulative Percent Drug Release 
F1 F2 F3 
0 0 0 0 
0.5 16.51±  0.62 15.45±  0.57 10.52±  0.64 
1 23.22±  0.49 21.47±  0.67 15.63±  0.57 
2 29.58±  0.69 27.56±  0.61 21.50±  0.60 
4 36.59±  0.68 33.66±  0.58 27.37±  0.62 
6 43.48±  0.67 40.42±  0.61 32.56±  0.59 
8 56.72.±  0.60 46.53.±  0.59 43.68.±  0.56 
10 63.52±  0.67 59.38±  0.47 54.62±  0.60 
12 70.48±  0.52 65.42±  0.55 60.49±  0.56 
24 91.36±  0.68 83.51±  0.52 71.55±  0.64 
 
 
 
                                 Fig 22  Comparative Dissolution Profile 
 
 
 
 
 
Table 21 In vitro release kinetic data for nevirapine loaded nanoparticles 
 
 
Formulation
 
 
Zero order
 
First order
 
Higuchi Matrix
Peppas plot 
r2   value ‘n’ value
 
1:1 
 
0.9927 0.9227 0.9758 0.9881 
 
0.7082 
 
1:2 
 
0.9930 0.9512 0.9741 0.9868 
 
0.7084 
 
1:4 
 
0.9971 0.9773 0.9764 0.9937 
 
0.7952 
 
    K0- Zero order rates constant 
  K1 – First order rate constant 
  R – Coefficient of correlation 
  N – Diffusion exponent 
The regression co-efficient values are zero order plots wew compared. It was 
observed that the “R” value of zero order plit were in the range of 0.9927 to 0.9971 from all 
the three formulations. The “R” values of first order plot were in the range of 0.9925 to 
0.9773, based on the highest regression values (R), the best fit model for F1, F2 and F3. 
Followed zero order release. The “R” value of the linear regression for korsmeyer plot were 
found in the range of 0.9881 to 0.9937 for all the formulation indicating that the data fit into 
the korsmeyer plot model well, and the drug release was found to be predominantely 
controlled by swelling process. 
When the slope n values of formulation F1,F2 and F3 in korsmeyer equation 
(F1=0.7082, F2=0.7084 and F3=0.7952) were compared, it was observed that increasing 
polymer concentration in the nanoparticle led to increase in the slope value from 0.7082 to 
0.7952 indicating that the drug release by case II transport mechanism. (n>1) class II 
transport mechanism which involves swelling controlled release of the drug. 
Turkey – Kramer multiple camparision test : t90 
The release data were subject to ANOVA with Turkey- Kramer comparision test F2 
showed release pattern as compared F1 (p<0.05) .Similar release behavior was observed 
between F3 and F1 (p<0.001) and between F3 and F2 (p<0.05).The result suggest that the 
 
 
slow drug release characterstics appear to be influenced by polymer concentration. Table 22, 
23.   
                                    Table 22  ANALYSIS OF VARIANTS 
Formulation code F1 F2 F3 
Mean 43.146 38.346 33.888 
Standard deviation 27.621 24.465 23.300 
sample size (N) 10 10 10 
std error of mean 8.735 7.736 7.368 
Lower 95% conf. limit 62.904 55.846 50.555 
upper 95% conf. limit 56.41 52.8 48.48 
Minimum 0 0 0 
Median 40.035 37.040 30.035 
Maximum 91.360 83.510 71.680 
Normality test KS 0.09518 0.1260 0.1212 
Normality test P value >0.10 >0.10 >0.10 
Passed normality test yes yes yes 
    Table 23 Turkey –kramer multiple comparison test:t90 
Comparision Mean difference “q” value “p” value 
F1 Vs F2 4.800 4.532 P< 0.05 
F1 Vs F3 9.258 8.742 P< 0.001 
F2 Vs F3 4.458 4.209 P< 0.05 
The “P” value is <0.0001, considered extremely significant. Variation among column means 
is significantly greater than expected by chance. 
  If the value q is greater than 3.609 then the p value is less than 0.05. 
 
 
9.4.2 DIFFUSION STUDIES: 
Cumulative percentage drug released for F1, F2 and F3 at 24 hrs was 92.40%, 83.43% 
and 76.23% (Table 24,26 and 28) respectively. The invitro release profile of all the 
formulation showed a slow and steady release pattern approximately in zero order release. 
There was no burst release observed in all the formulations indicating absence of drug load 
along the surface of the nanoparticles. 
The release data were subjected to ANOVA with Tukey –Kramer multiple 
comparison test. F3 showed slower release pattern as compared to F2 (p<0.001). Similar 
release behavior was observed between F2 and F1 (p<0.001), and between F3 and F1 (p< 
0.001). The results suggest that the slow drug release characteristic appears to be influenced 
by polymer molecular weight. 
The t50 values of F1, F2 and F3 were also compared. The data are F1 Vs F2 (P>0.05); 
F1 Vs F3 (P<0.001); F2 Vs F3 (P<0.01). There was no significant difference in t50   value 
between F1 and F2, however significant differences observed between F2 and F3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 24 In vitro release data for nevirapine nanoparticles (F1) 
Time 
(hrs) 
       Cumulative Percent Drug Release 
Trial 1 Trial 2 Trial 3 Mean ± SD 
 0 0 0 0 0 
0.5  1.735 1.731 1.738 1.739±  0.0035 
1 4.932 4.921 4.925 4.922±  0.0055 
2 9.786 9.685 9.689 9.686±  0.0571 
3 15.489 15.475 15.484 15.485±  0.0070 
4 25.549 25.531 25.531 25.535±  0.0110 
6 30.189 30.179 30.179 30.182.±  0.0682 
8 37.398 37.398 37.392 37.394±  0.0030 
10 43.141 43.132 43.132 43.129±  0.0062 
12 49.998 49.986 49.986 49.996±  0.0061 
14 52.238 52.241 52.241 52.238±  0.0035 
16 58.490 58.481 58.481 58.491±  0.0045 
18 68.835 68.821 68.821 68.825± 0.0073 
20 77.579 77.569 77.565 77.572± 0.0072 
22 84.792 84.785 84.784 84.789± 0.0007 
24 92.412 92.401 92.402 92.407± 0.0060 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 23 Percentage Drug Release 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 25 Kinetic release data for nevirapine nanoparticles (F1) 
ime in 
hrs 
Square 
root of 
time 
Log 
time 
 
Cumulative 
%drug 
release 
Log 
cumulative 
%drug 
release 
Cumulative 
%drug 
remaining 
Log 
cumulative 
%drug 
remaining 
0 0 0 0 0 100 2 
0.5 0.707 -0.301 1.73 0.238 99.76 1.998 
1 1 0 4.92 0.691 99.3 1.996 
2 1.414 0.301 9.68 0.985 99.01 1.995 
3 1.732 0.477 15.48 1.189 98.81 1.994 
4 2 0.602 25.53 1.407 98.59 1.993 
6 2.449 0.778 30.17 1.479 98.52 1.993 
8 2.828 0.903 37.39 1.572 98.42 1.993 
10 3.162 1 43.12 1.634 98.36 1.992 
12 3.464 1.079 49.98 1.698 98.3 1.992 
14 3.741 1.146 52.24 1.718 98.28 1.992 
16 4 1.204 58.48 1.767 98.23 1.992 
18 4.242 1.255 68.82 1.837 98.16 1.991 
20 4.472 1.301 77.56 1.889 98.11 1.991 
22 4.69 1.342 84.78 1.928 98.07 1.991 
24 4.898 1.38 92.4 1.965 98.03 1.991 
 
 
 
 
 
 
 
 
 
 
 
Fig 24 (a) 
 
 
 
Fig 24 (b) 
 
 
 
 
 
 
 
 
 
Fig 24 (c) 
 
 
 
 
Fig 24 (d) 
 
 
 
 
 
 
Table 26 In vitro release data for nevirapine nanoparticles(F2)  
 
                                                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time 
(hrs) 
         Cumulative Percent Drug Release 
Trial 1 Trial 2 Trial 3 Mean ± SD 
 0 0 0 0 0 
0.5 1.381 1.372 1.374 1.376±  0.0047 
1 3.512 3.492 3.494 3.500±  0.0110 
2 8.782 8.772 8.776 8.777±  0.0050 
3 13.959 13.929 13.925 13.932±  0.0185 
4 22.841 22.819 22.816 22.823±  0.194 
6 29.551 29.521 29.525 29.536±  0.016 
8 36.998 36.996 36.999 36.997±  0.0015 
10 42.865 42.853 42.858 42.859±  0.0060 
12 48.441 48.432 48.429 48.437±  0.0062 
14 51.102 51.106 51.114 51.110±  0.583 
16 57.815 57.809 57.804 57.810±  0.0055 
18 62.401 62.381 62.382 67.383± 0.011 
20 69.639 69.629 69.622 69.360± 0.0085 
22 75.784 75.759 75.752 75.762± 0.0168 
24 83.441 83.429 83.424 83.432± 0.0083 
 
 
 
 
 
 
 
 
 
 
 
      Fig 25 Percentage of Drug Release 
 
 
 
 
 
 
 
 
 
 
 
 
Table 27  Kinetic release data for nevirapine nanoparticles (F2) 
Time 
in hrs 
Square 
root of 
time 
Log 
time 
 
Cumulative 
%drug 
release 
Log 
cumulative 
%drug 
release 
Cumulative 
%drug 
remaining 
Log 
cumulative 
%drug 
remaining 
0 0 0 0 0 100 2
0.5 0.707 -0.301 1.37 0.136 99.86 1.999
1 1 0 3.5 0.544 99.45 1.997
2 1.414 0.301 8.77 0.942 99.05 1.995
3 1.732 0.477 13.92 1.143 98.85 1.994
4 2 0.602 22.81 1.358 98.64 1.994
6 2.449 0.778 29.52 1.47 9853 1.993
8 2.828 0.903 36.99 1.568 98.43 1.993
10 3.162 1 42.85 1.631 98.36 1.992
12 3.464 1.079 48.42 1.685 98.31 1.992
14 3.741 1.146 51.11 1.708 98.29 1.992
16 4 1.204 57.81 1.762 98.23 1.992
18 4.242 1.255 62.38 1.795 98.2 1.992
20 4.472 1.301 69.62 1.842 98.15 1.991
22 4.69 1.342 75.75 1.879 98.12 1.991
24 4.898 1.38 83.42 1.921 98.07 1.991
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 26 (a) 
 
 
 
 
Fig 26 (b) 
 
 
 
 
 
 
 
 
Fig 26 (c) 
 
 
 
 
 
Fig 26 (d) 
 
 
 
 
 
Table 28  In vitro release data  for nevirapine nanoparticles (F3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time 
(hrs) 
         Cumulative Percent Drug Release 
Trial 1 Trial 2 Trial  3   Mean ± SD 
 0 0 0 0 0 
0.5 1.311 1.299 1.298 1.304±  0.0072 
1 3.252 3.239 3.235 3.241±  0.0088 
2 7.628 7.612 7.609 7.618±  0.0102 
3 13.162 13.153 13.149 13.157±  0066 
4 20.389 20.371 20.368 20.375±  0.0113 
6 27.735 27.721 27.719 27.729±  0.0087 
8 36.621 36.594 36.598 36.604±  0.0145 
10 41.441 41.429 41.432 41.435±  0.0062 
12 46.252 46.238 46.232 46.240±  0.0102 
14 50.795 50.785 50.781 50.790±  0.0072 
16 57.935 57.919 57.912 57.925±  0.0117 
18 63.875 63.859 63.56 63.864± 0.0102 
20 67.829 67.814 67.809 67.817± 0.0104 
22 71.856 71.839 71.841 71.840± 0.0087 
24 76.245 76.231 76.229 76.239± 0.0092 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 27 Percentage of Drug Release 
 
 
 
 
 
 
 
 
 
 
 
Table 29     Kinetic release data for nevirapine nanoparticles (F3) 
Time 
in hrs 
Square 
root of 
time 
Log 
time 
 
Cumulative 
%drug 
release 
Log 
cumulative 
%drug 
release 
Cumulative 
%drug 
remaining 
Log 
cumulative 
%drug 
remaining 
0 0 0 0 0 100 2 
0.5 0.707 -0.301 1.3 0.123 99.87 1.994 
1 1 0 3.24 0.51 99.49 1.997 
2 1.414 0.301 7.61 0.881 99.11 1.996 
3 1.732 0.477 13.15 1.118 98.88 1.995 
4 2 0.602 20.37 1.308 98.69 1.994 
6 2.449 0.778 27.72 1.442 98.55 1.993 
8 2.828 0.903 36.6 1.563 98.43 1.993 
10 3.162 1 41.43 1.617 98.38 1.992 
12 3.464 1.079 46.24 1.665 98.33 1.992 
14 3.741 1.146 50.79 1.705 98.29 1.992 
16 4 1.204 57.92 1.762 98.23 1.992 
18 4.242 1.255 63.86 1.805 98.19 1.992 
20 4.472 1.301 67.81 1.831 98.16 1.991 
22 4.69 1.342 71.84 1.856 98.14 1.991 
24 4.898 1.38 76.23 1.882 98.11 1.991 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 28 (a) 
 
 
 
Fig 28 (b) 
 
 
 
 
 
 
 
 
 
Fig 28 (c) 
 
 
 
Fig 28 (d) 
 
 
 
 
 
Table 30  Compartivie study for diffusion of nevirapine nanoparticles 
Time (hrs) 
Cumulative Percent Drug Release 
F1 F2 F3 
0 0 0 0 
0.5 1.739 1.376 1.304 
1 4.922 3.500 3.241 
2 9.686 8.777 7.618 
3 15.485 13.932 13.157 
4 25.535 22.823 20.375 
6 30.182. 29.536 27.729 
8 37.394 36.997 36.604 
10 43.129 42.859 41.435 
12 49.996 48.437 46.240 
14 52.238 51.110 50.790 
16 58.491 57.810 57.925 
18 68.825 67.383 63.864 
20 77.572 69.360 67.817 
22 84.789 75.762 71.840 
24 92.407 83.432 76.239 
 
 
 
 
 
 
 
 
 
Fig 29  COMPARATIVE DIFFUSION PROFILE 
 
Table 31 In vitro release kinetic data nevirapine loaded nanoparticles 
(DIFFUSION) 
Formulation 
code 
First 
order 
“R2”value
Zero 
order 
“R2”value
Higuchi 
plot 
“R2”value
Peppas 
plot 
“R2”value
n  value 
 
F1 
 
0.9754 
 
0.9865 
 
0.9759 
 
0.9813 
 
1.0778 
 
F2 
 
0.9821 
 
0.9890 
 
0.9802 
 
0.9886 
 
1.0828 
 
F3 
 
0.9880 
 
0.9946 
 
0.9730 
 
0.9925 
 
1.0942 
 
 
 
 
 
K0- Zero order rates constant 
  K1 – First order rate constant 
  R – Coefficient of correlation 
  N – Diffusion exponent 
The regression co-efficient values are zero order plots wew compared. It was 
observed that the “R” value of zero order plit were in the range of 0.9865 to 0.9946 from all 
the three formulations. The “R” values of first order plot were in the range of 0.9754 to 
0.9880, based on the highest regression values (R), the best fit model for F1, F2 and F3. 
Followed  zero order release. The “R” value of the linear regression for korsmeyer plot were 
found in the range of 0.9813 to 0.9925 for all the formulation indicating that the data fit into 
the korsmeyer plot model well, and the drug release was found to be predominantely 
controlled by swelling process. 
When the slope n values of formulation F1,F2 and F3 in korsmeyer equation 
(F1=1.0778, F2=1.0828 and F3=1.0942) were compared, it was observed that increasing 
polymer concentration in the nanoparticle led to increase in the slope value from 0.7082 to 
0.7952 indicating that the drug release by case II transport mechanism. (n>1) class II 
transport mechanism which  involves swelling controlled release of the drug. 
Turkey – Kramer multiple camparision test : t90 
The release data were subject to ANOVA with Turkey- Kramer comparision test F2 
showed release pattern as compared F1 (p<0.05) .Similar release behavior was observed 
between F3 and F1 (p<0.001) and between F3 and F2 (p<0.05).The result suggest that the 
slow drug release characterstics appear to be influenced by polymer concentration. Table  
32,33.   
 
 
 
 
 
 
 
 
Table 32  ANALYSIS  OF VARIANTS 
Formulation code F1 F2 F3 
Mean 40.767 38.015 36.631 
Standard deviation 30.235 27.680 26.749 
sample size (N) 20 20 20 
std error of mean 7.559 6.920 6.687 
Lower 95% conf. limit 24.660 23.269 22.381 
upper 95% conf. limit 56.575 52.761 50.883 
Minimum 0 0 0 
Median 40.255 39.920 39.015 
Maximum 92.400 83.420 76.230 
Normality test KS 0.1110 0.1205 0.1225 
Normality test P value >0.10 >0.10 >0.10 
Passed normality test yes yes yes 
 
Table 33 Turkey – Kramer multiple comparison test: t90 
Comparision Mean difference “q” value “p” value 
F1 Vs F2 2.753 4.401 P< 0.05 
F1 Vs F3 4.136 6.612 P< 0.001 
F2 Vs F3 1.383 2.211 P> 0.001 
 The “P” value is <0.0001, considered extremely significant. Variation among column 
means is significantly greater than expected by chance. 
If the value q is greater than 3.486 then the p value is less than 0.05.  
 
 
 
HPLC graphs 
Chromatograms of Nevirapine alone 
0.5 hr              1hr 
         
Fig 30 (a)        Fig30 (b)  
 
 
 
 
1.5 hr              2 hr 
       
                    Fig 30 (c)       Fig 30 (d) 
 
 
 
 
         
2.5 hr                        3 hr 
      
                      Fig 30 (e)                Fig 30 (f) 
 
 
 
 
3.5 hr                4 hr 
         
Fig 30 (g)        Fig 30 (h) 
 
 
 
 
 
5 hr          6 hr
                  
Fig 30 (i)       Fig 30 (j) 
 
 
 
 
8 hr              10 hr 
                               
Fig 30 (k)       Fig 30 (l) 
   
 
 
 
12.0 hr       24.0 hr 
                 
                     Fig 30 (m)           Fig 30 (n) 
                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chromatograms of  Nevirapine Nanoparticles 
0.5 hr              1 hr 
                     
Fig 31 (a)       Fig 31 (b) 
 
 
 
1.5 hr                2 hr 
       
Fig 31 (c)       Fig 31 (d) 
 
 
 
 
 
2.5 hr          3 hr
                
Fig 31 (e)       Fig 31 (f) 
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5HR                6HR 
       
Fig 31 (i)       Fig 31 (j) 
 
 
 
 
8HR              10HR 
                    
Fig 31 (k)       Fig 31 (l) 
 
 
 
 
 
12.0          14.0
           
Fig 31 (m)       Fig 31 (n) 
 
 
 
 
 
 
16.0                20.0 
                         
Fig 31 (o)       Fig 31 (p) 
 
 
 
 
24.0 
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Table 34  Peak area of test plasma samples of Group I at various time intervals 
Peak area of Nevirapine 
 
Time
(hr) 
 Peak area 
 
1 
 
 
 
 
2 
 
3 
 
4 
 
5 
 
6 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
3.5 
4.0 
5.0 
6.0 
8.0 
10.0 
12.0 
24 
5613 
10920 
15920 
20100 
24900 
28900 
32400 
35600 
40100 
45600 
34600 
20900 
10900 
0 
4314 
10520 
14800 
21500 
25100 
29720 
35000 
36200 
41500 
45720 
33191 
21200 
11200 
0 
6096 
11120 
16180 
21720 
21720 
27600 
33200 
36790 
42600 
45900 
30161 
21600 
12500 
0 
7291 
11500 
16720 
20900 
20900 
30100 
34900 
35490 
440600 
45600 
32191 
22800 
13600 
0 
8695 
10200 
16900 
20780 
20780 
28620 
32600 
34600 
43500 
44900 
33397 
21500 
15600 
0 
5790 
10620 
15900 
20600 
25180 
28700 
32750 
35910 
41200 
28950 
29500 
21800 
14900 
0 
 
 
 
 
 
 
 
 
 
Table 35                Peak area of Nevirapine nanoparticles 
 
Time
(hr) 
 Peak area 
 
1 
 
 
 
 
2 
 
3 
 
4 
 
5 
 
6 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
3.5 
4.0 
5.0 
6.0 
8.0 
10.0 
12.0 
14.0 
16.0 
20.0 
24.0 
15200 
21900 
25620 
32600 
25620 
45200 
52100 
60720 
66720 
72500 
65000 
52100 
42800 
32500 
26500 
20800 
15100 
16720 
20700 
27510 
33100 
27510 
45600 
53600 
60900 
67900 
73400 
66900 
53500 
43550 
34800 
24800 
20500 
14600 
15910 
21200 
28900 
34600 
28900 
45720 
51900 
61290 
68920 
71600 
67500 
54600 
46800 
33500 
23700 
20900 
14000 
17200 
25600 
29500 
35200 
29500 
46100 
54240 
62500 
69920 
73600 
68390 
55700 
48900 
37600 
28900 
21600 
14500 
15920 
24600 
25720 
31700 
25720 
47200 
56920 
61900 
69790 
75200 
69310 
54720 
49500 
30900 
21400 
22400 
14800 
18610 
25700 
26100 
32720 
26100 
45100 
55710 
64590 
68720 
71900 
65582 
55600 
47600 
35400 
25100 
20000 
16900 
 
 
 
 
 
 
Table 36 Plasma concentration of test samples in Group I at various time intervals 
Plasma concentration of Nevirapine 
 
Time(hr) 
 Animals  
Mean±S.E.M 
 
 
1 
 
  
2 
 
3 
 
4 
 
5 
 
6 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
3.5 
4.0 
5.0 
6.0 
8.0 
10.0 
12.0 
24.0 
0.05 
0.3 
1.0 
1.85 
3.0 
4.0 
5.0 
6.0 
6.8 
5.6 
4.0 
1.85 
0.05 
0 
0.15 
0.9 
2.0 
2.7 
3.4 
4.4 
4.9 
5.8 
6.4 
6.0 
4.2 
2.7 
0.15 
0 
0.06 
0.5 
1.4 
2.0 
2.9 
4.1 
4.8 
5.7 
6.6 
5.7 
3.9 
2.0 
0.06 
0 
0.14 
0.7 
1.6 
1.9 
3.5 
4.3 
5.4 
6.1 
6.9 
5.5 
4.3 
1.9 
0.14 
0 
 
0.05 
0.4 
1.3 
2.3 
3.1 
3.9 
5.3 
6.2 
6.2 
6.1 
3.8 
2.3 
0.05 
0 
0.15 
0.8 
1.7 
1.98 
3.3 
4.5 
5.2 
5.6 
6.0 
5.9 
4.4 
1.98 
0.15 
0 
0.1±0.02098 
0.6±0.09661 
1.5±0.14140 
2.1±0.13220 
3.2±0.09611 
4.5±0.14240 
5.1±0.09661 
5.9±0.09661 
6.5±0.14240 
5.8±0.09661 
4.1±0.09661 
2.1±0.13220 
0.1±0.02098 
0 
 
 
 
 
 
 
 
 
 
 
Table 37       Pharmacokinetic parameters of  Nevirapine alone 
S.no Parameters Animals  
Mean±S.E.M 1 2 3 4 5 6 
1 Cmax 6.8 6.4 6.6 6.9 6.2 6 6.85±0.15940 
2 Tmax 4.5 4.5 4.5 4.5 4.0 4.5 4.89±0.08333 
3 AUC0-24 30.15 36.42 30.63 34.66 31.95 33.78 34.26±0.76640
4 keli (h-1) 0.344 0.335 0.322 0.358 0.339 0.345 0.304±0.004 
5 AUC0-∞ 45.44 54.51 46.27 51.90 46.07 50.13 49.05±1.51400
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 38  Plasma concentration of Nevirapine Nanoparticles 
 
Time(hr) 
 Animals  
Mean±S.E.M 
 
 
1 
 
  
2 
 
3 
 
4 
 
5 
 
6 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
3.5 
4.0 
5.0 
6.0 
8.0 
10.0 
12.0 
14.0 
16.0 
20.0 
24.0 
0.04 
0.3 
0.51 
1.04 
1.4 
2.0 
2.4 
3.0 
3.8 
4.1 
7.0 
6.4 
0.05 
 4.0 
3.0 
1.4 
0 
0.05 
0.2 
0.52 
1.05 
1.5 
2.1 
2.5 
3.1 
3.9 
4.2 
7..1 
6.5 
5.8 
4.1 
3.1 
1.5 
0.1 
0.06 
0.4 
0.53 
1.06 
1.6 
2.2 
2.6 
3.2 
4.0 
4.3 
7.2 
6.6 
5.9 
4.2 
3.2 
1.6 
0.2 
0.03 
0.4 
0.50 
1.03 
1.3 
1.9 
2.3 
2.9 
3.7 
4.0 
6.9 
6.3 
5.6 
3.9 
2.9 
1.3 
0 
0.05 
0.3 
0.52 
1.05 
1.5 
2.1 
2.5 
3.1 
4.0 
4.2 
7.1 
6.5 
5.8 
4.1 
3.1 
1.5 
0.1 
0.07 
0.2 
0.54 
1.07 
1.7 
2.3 
2.7 
3.3 
4.2 
4.4 
7.3 
6.7 
6.0 
4.3 
3.3 
1.7 
0.3 
0.05±0.005774 
0.3±0.036510 
0.52±0.005774 
1.05±0.05774 
1.5±0.057740 
2.1±0.057440 
2.5±0.057740 
3.1±0.057440 
3.9±0.071490 
4.2±0.057740 
7.1±0.071490 
6.5±0.057740 
5.8±0.057740 
4.1±0.057440 
3.1±0.057440 
1.5±0.057740 
0.1±0.047730 
 
 
 
 
 
 
 
 
Table 39    Pharmacokinetic parameters Nevirapine nanoparticles 
 
S.no Parameters Animals  
Mean±S.E.M 1 2 3 4 5 6 
1 Cmax 7.0 7.1 7.2 6.9 7.1 7.3 7.1±0.058 
2 Tmax 8.0 8.0 8.0 8.0 8.0 8.0 8.0±0.00 
3 AUC0-24 82.69 84.78 87.12 81.05 85.01 87.48 84.69±1.017 
4 keli (h-1) 0.14 0.136 0.132 1.146 0.135 0.128 0.14±0.003 
5 AUC0-∞ 101.34 120.46 110.78 115.52 125.67 109.93 113.9±3.50 
 
 
 
 
 
 
Table 40  Comparative Pharmacokinetic parameters of Nevirapine and Nevirapine    
Nanoparticles 
S.no Parameters Nevirapine Nevirapine 
Nanoparticles 
1 Cmax 6.85±0.15940 7.1±0.058 
2 Tmax 4.89±0.08333 8.0±0.00 
3 AUC0-24 34.26±0.76640 84.69±1.017 
4 keli (h-1) 0.304±0.004 0.14±0.003 
5 AUC0-∞ 49.05±1.51400 113.9±3.50 
 
 
 
 
 
 
9.5 Pharmacikinetics of nevirapine and nevirapine nanoparticles: 
9.5.1 Cmax of nevirapine alone and nevirapine nanoparticles 
 The mean Cmax values of NVP amd nevirapine nanoparticles are respectively 
6.85±0.15940 and 7.1±0.058 . There is extremely significant (P<0.001) increase in Cmax of 
NVP alone when compared with nevirapine nanoparticles group and extremely significant 
(P<0.001) increase in Cmax when compared with NVP  group. 
Table. 41  Cmax of   nevirapine and nevirapine nanoparticles 
S.NO GROUP Cmax(µg/ml)  
Mean±S.E.M 
   1 
2 
NVP alone 
NVP NP 
6.85±0.15490b
7.1±0.058a 
 
The values are expressed as mean±SEM; a=P<0.001; b=P<0.001 when compared 
with NVP alone, NVP NP group (one way ANOVA followed by Tukey’s multiple 
comparision test) 
 
                                            Fig 32 Cmax of  in NVP and nevirapine nanoparticles 
 
 Cmax of NVP alone, NVP NP.The values are expressed as mean±SEM; ***P<0.001; 
*** P<0.001 when compared with NVP alone and NVP NP group, (one way ANOVA 
followed by Tukey’s multiple comparision test). 
 
 
 
9.5.2 Tmax of Nevirapine (NVP) and Nevirapine nanoparticles (NVP NP) 
The mean Tmax values of NVP, NVP NP are respectively 4.89±0.08333 and 8.0±0.00. 
There is extremely significant (P<0.001) increase in Cmax of NVP alone when compared with 
nevirapine nanoparticles group and extremely significant (P<0.001) increase in Cmax when 
compared with NVP  group. 
Table. 42  Tmax of  NVP ,and NVP NP 
 
S.NO GROUP Cmax(hr-1)  
Mean±S.E.M 
1 
2 
NVP alone 
NVP NP 
4.89±0.0833b
8.0±0.00a 
 
The values are expressed as mean±SEM; a=P<0.001; b= P<0.001 when compared with NVP 
alone, NVP NP  group (one way ANOVA followed by Tukey’s multiple comparision test). 
 
     Figure 33 Tmax of  NVP  and NVP NP 
 Tmax of NVP alone, NVP NP.The values are expressed as mean±SEM; a=P<0.001;b= 
P<0.001 when compared with NVP alone and NVP NP group, (one way ANOVA followed 
by Tukey’s multiple comparision test). 
 
 
 
9.5.3 AUC0-24 of  NVP  and NVP NP 
The mean AUC0-24 values of NVP and NVP NP are respectively 34.26±0.76640 and 
84.69±1.017. There is extremely significant (P<0.001) increase in Cmax of NVP alone when 
compared with NVP NP group and extremely significant (P<0.001) increase in AUC0-24 of 
NVP NP group when compared with NVP group.  
Table 43  AUC0-24 of nevirapine alone and nevirapine nanoparticles 
S.NO GROUP AUC0-24 
Mean±S.E.M 
1 
2 
           NVP alone 
NVP NP 
34.26±0.76640b
84.69±1.017a 
 
 The values are expressed as mean±SEM; a=P<0.001; b= P<0.001 when compared with NVP 
alone, NVP NP group. (one way ANOVA followed by Tukey’s multiple comparision test) 
 
Figure 34   AUC0-24 of nevirapine alone and nevirapine nanoparticles 
 
 AUC0-24 of nevirapine in NVP alone nevirapine nanoparticles; The values are 
expressed as mean±SEM; a=P<0.001; b= P<0.001 when compared with NVP alone, NVP NP 
group. (one way ANOVA followed by Tukey’s multiple comparision test). 
 
9.5.4 Ke (hr-1) of  nevirapine alone, and nevirapine nanoparticles 
 
 
The mean Ke (hr-1) values of NVP, NVP NP are respectively 0.304±0.004 and 
0.14±0.003 . There is very significant (P<0.001) increase in Cmax of NVP alone when 
compared with NVP NP group . 
 
Table. 44  Ke (hr-1) of  in NVP alone, NVP NP 
 
S.NO GROUP Ke (hr-1) 
Mean±S.E.M 
    1 
2 
NVP alone 
NVP NP 
0.304±0.004 b
0.14±0.003 a 
 The values are expressed as mean±SEM; a=P<0.01; b= P<0.001 when compared with NVP 
alone, NVP NP group. (one way ANOVA followed by Tukey’s multiple comparision test) 
 
           Figure  35  Ke (hr-1) of  in NVP alone, NVP NP 
 
Ke (hr-1) of nevirapine alone, NVP NP. The values are expressed as mean±SEM; 
a=P<0.01; **b= P<0.001 when compared with NVP alone, NVP NP group. (one way 
ANOVA followed by Tukey’s multiple comparision test). 
9.5.5 AUC0-∞ of nevirapine and nevirapine nanoparticles 
 
 
The mean AUC0-∞ values of NVP and NVP NP are respectively 49.05±1.51400 and 
113.9±3.50 . There is extremely significant (P<0.001) increase in Cmax of NVP alone when 
compared with NVP NP group.  
Table 45   AUC0-∞of nevirapine and nevirapine nanoparticles 
 
S.NO GROUP AUC0-∞  
Mean±S.E.M 
1 
2 
NVP alone 
NVP NP 
49.05±1.51400 b
113.9±3.50 a 
 
  The values are expressed as mean±SEM; a=P<0.001; b= P<0.001 when compared 
with NVP alone, NVP NP group. (one way ANOVA followed by Tukey’s multiple 
comparision test). 
 
             Figure 36 AUC0-∞of nevirapine and nevirapine nanoparticles 
 
  AUC0-∞of nevirapine and nevirapine nanoparticles. The values are expressed as 
mean±SEM; a=P<0.001; b= P<0.001 when compared with NVP alone, NVP NP group. (one 
way ANOVA followed by Tukey’s multiple comparision test). 
 
      
 
 
10.0 DISCUSSION 
The results of the present study demonstrated that delivery of nevirapine as 
nanoparticles loaded in humanserumalbumin (HSA) could be beneficial to improve the 
physical characteristics of the drug and thus improve the bio availability of nevirapine. 
Nevirapine is recommended in combination therapy with other anti HIV drugs in the initial 
regimen to reduce impacts on the clinical implications of drug resistance (Mugavero C.B 
Hicks et al 2004)72. 
Currently nevirapine is available as tablets and  pediatric oral suspensions. Owing to 
poor bioavailability nevirapine may not control the HIV infection effectively. Focusing on 
this in the present study an attempt was made to develop nanoparticles of nevirapine using 
HSA as a polymer. Nanoparticles were prepared by desolvation method in which no organic 
solvent was employed and as such the developed nanoparticles are free of any toxic effects 
that are common with organic solvents used in the preparation method. In  addition, the 
desolvation- chemical crosslinking method can keep drug activity while enveloping the drug 
in the nanoparticles. (D.Chen et al 2010)73 
The encapsulation efficiency and percentage yield of the nanoparticles were found 
influenced by HSA concentration; both parameters were increased with increasing HSA 
concentration. During the formation of nanoparticles the NVP might be undergoing shift 
from crystallanity to amorphous in the polymer HSA and therefore the increasing 
encapsulation efficiency and percentage yield with increase in HSA concentration. The DSC 
thermogram showed characteristic change in the endothermic peak of nevirapine showing 
amorphous form of the drug that helps in influencing the encapsulation efficiency and 
percentage yield of nanoparticles. The particle was found discrete and irregular at all 
concentration of polymer, however with increase in size of particles as the concentration of 
HSA increased. The particle size increased with increase in HSA concentration. The particle 
site of nanoparticles depend upon that techniques followed for preparation of nanopartilces 
and other factors such as the type of crosslinking agent and the desolvating agent used. It has 
been reported that the amount of desovating agent ethanol in the desolvation process was 
found to control particle size (Langer K et al 2003)74. In this study the amount of 
desolvating agent ethanol  was used at a fixed volume and therefore its influence on the size 
of the nanoparticles is unlikely. It has also been reported that rate of ethanol addition also 
influence particle size; however in the study ethanol addition was not measured and therefore 
its influence on the site of nanoparticles could not be established clearly. The size of the 
 
 
nanoparticles ranged from 298  025nm to 698  0.52 nm (Table 13). An increase in particle 
site was evident with increase in HSA concentration. As other variables such as the amount 
of desolvating agent ethanol, the rate of addition of ethanol, the stirring speed  used were not 
controlled in the preparation of nanoparticles in the present study and therefore the role of 
HSA concentration (though influenced particle size) on the size of nanoparticles could not be 
clearly defined.  
The PDI of nanoparticles ranged between 0.195 and 0.435 (Table 13) which indicates 
a homogenous dispersion of the drug; the PDI was found increased with increasing the HSA 
concentration indicating that higher concentration of the polymer detrimental to homogenous 
dispersion  of the drug. This may be another reason pointing to suggest that the particle size 
of the nanoparticles depending on the HSA concentration. 
Surface characterstics of the nanoparticles greatly influence their intereaction with the 
biological memberane, besides the stability of nanoparticles. Zeta potential is an index of the 
stability of the nanoparticles under most conditions, the higher the absolute value of the zeta 
potential of the nanoparticles, the larger the charge on their surface, leading to stronger 
repulsive interaction between  the dispersed nanoparticles and higher stability  and more 
uniform size. It has also been demonstrated that a high potential value of above 25mv, 
ensures a high energy barrier that stabilizes the nanosuspension (Muller R.H. et al)75. A 
lower zeta potential (less than 0.25mv) observed in the formulations F2  & F3  may be another 
factor influencing the particle site of nanoparticles in these  formulations. The nano size 
initially formed during the preparation of nanoparticles formed aggregates to grow in size due 
to instability of the nanoparticles with low zeta potential which was evident in F2 & F3. 
A variable dissolution profile of formulations F1, F2 and F3 was observed. All 
formulations showed slow dissolution of nevirapine. The mean dissolution time of  F1,  F2  & 
F3 was 27.69, 27.63 and 28.28 respectively  and each value  was found to be close to that of 
other, and  as such the mean dissolution time of nevirapine was comparatle between F1,  F2  & 
F3. However the percentage of nevirapine release was highest 91.36% (Table 14 and fig 15) 
from F1, and lowest 71.55 (Table 18, and fig 20)  from F3 formulation. The percentage of 
nevirapine  release from F2 was 83.51 (Table 16 and fig 17) . All the formulations showed 
zero order release kinetic with r2 value about 0.99. The variation in percent drug release at 
different time point intervals, in different formulations may be due to the HSA concentration 
used.The factors influencing the dissolution of nevirapine can be stated as follows. 1. Particle 
 
 
size place as important role in influencing the dissolution of the drug in the environment. The 
particle size was least in F1 298 nm(fig 14) as compared to that in F2 495nm(fig 15) and F3 
698nm (fig 16). Therefore it is obvious that a higher percent of nevirapine was released from 
F1 as compared to  F2 & F3. Other factors such as pH of the environment can also influence 
the dissolution of drug. However in the present study all formulations showed slow 
dissolution which was found to be independent of pH of the environment. These observations 
suggest that HSA nanoparticles release the drug at a rate independent of the pH of the 
environment.  
The in-vitro dissolution profile of F1, F2 & F3 was also reflected in the diffusion study. 
The percentage drug diffused from F1, F2 & F3 was 92.40%. 83.43% and 76.23% (Table 
24,26 and 28) respectively. These findings propose that factors particularly particle size of 
nanoparticles did also influenced the  diffusion of drug which was found to be dependent 
upon the HSA concentration. There was no burst release of drug from all the formulations 
and showed a near perfect zero order release of the nanoparticles. 
Based on the dissolution and diffusion characteristics the formulation F1 was found to 
be  the ideal formulation for further in-vivo study. According to FDA guidelines a controlled 
release formulation should release 0-20% at 4 h, 15-70% at 12 h and > 85% at 24h. 
Accordingly a formulation F1 was found to satisfy the above requirement compared to F2 & 
F3 and as such the formulation F1 was selected for the in-vivo pharmacokinetic study. The 
Cmax of F1 was found to be greater than nevirapine alone (P>0.001). Similarly the AUCo-24 
and AUCo-∞ of F1 were significantly higher than that of neverapine alone and the difference 
was statically Significant (P<0.001).The above findings clearly indicates that the 
bioavailability of nevirapine was found to be better from nanoparticles as compared to 
nevirapine alone. The increase in bioavailabity of nevirapine nanoparticles can be attributed 
to the following factors. 1. The size of nanoparticles (F1) is  for lesser than the size of pure 
nevirapine which is normally in micron range. 2. The human serum albumin may help better 
intereaction of the loaded nevirapine with the biological membrane that facilities improved 
permeability of the drug. 3. The drug particle was in the amorphous state in the nanoparticles 
as observed from the results the DSC study since amorphous drug is more soluble than the 
pure crystalline nevirapine. 
The Tmax of nanoparticles of (F1) was significantly higher than that of nevirapine 
alone (P<0.001). This is because the concentration of the drug for absorption was slowed by 
 
 
the effect of HSA. The Tmax of F1 was increased, and this was further evident from the 
reduced Ke value of nanoparticles as compared that of nevirapine alone.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11.0 Conclusion 
The present study reveals that nevirapine loaded human serum albumin(HSA)  
nanoparticles released the drug at slow and controlled rate with improved pharmacokinetics 
of nevirapine. The release rate and surface characterstics of  nanoparticles was found to be 
influenced by the HSA concentration. Thus it can be concluded that   nevirapine loaded- HSA 
nanoparticles is beneficial in improving bioavailability of drug as compared to conventional 
tablet dosage form. Further studies in humans are recommended for clinical outcome with 
this nanoparticle. 
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